haloperidol has been researched along with Delirium in 328 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Delirium: A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The AID-ICU trial was a randomised, blinded, placebo-controlled trial investigating effects of haloperidol versus placebo in acutely admitted, adult patients admitted in intensive care unit (ICU) with delirium." | 9.69 | Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Citerio, G; Collet, MO; Damgaard, K; Dey, N; Granholm, A; Hästbacka, J; Jensen, TB; Mathiesen, O; Morgan, M; Nielsen, LG; Pedersen, HS; Perner, A; Poulsen, LM; Sommer, T; Uslu, B; Weber, SO, 2023) |
| "This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital." | 9.69 | Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023) |
| "The role of haloperidol as treatment for ICU delirium and related symptoms remains controversial despite two recent large controlled trials evaluating its efficacy and safety." | 9.69 | Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. ( Boer, DP; Brouwers, AJBW; Devlin, JW; Gommers, DAMPJ; Hunfeld, NGM; Lens, JA; Osse, RJ; Ponssen, HH; Rietdijk, WJR; Schoonderbeek, JF; Simons, KS; Slooter, AJC; Smit, L; Trogrlic, Z; van den Boogaard, M; van der Jagt, M, 2023) |
| "Haloperidol is frequently used to treat delirium in patients in the intensive care unit (ICU), but evidence of its effect is limited." | 9.51 | Haloperidol for the Treatment of Delirium in ICU Patients. ( Aagaard, SR; Andersen-Ranberg, NC; Andreasen, AS; Bestle, MH; Brand, B; Brix, H; Caballero, J; Citerio, G; de Haas, I; Ebdrup, BH; Engstrøm, J; Eriksen, AS; Estrup, S; Fjeldsøe-Nielsen, H; Gramstrup Nielsen, L; Hästbacka, J; Haurum, C; Hildebrandt, T; Hyttel-Sørensen, S; Jensen, JV; Kingo Vesterlund, G; Kjær, MN; Kuivalainen, AM; La Cour, K; Laigaard, J; Lange, T; Mathiesen, O; Mikkelsen, VS; Morgan, M; Mortensen, CB; Nebrich, L; Nielsen, LO; Olesen, MW; Olsen, MH; Overgaard-Steensen, C; Oxenbøll Collet, M; Perner, A; Poulsen, LM; Rasmussen, BS; Scharling Pedersen, H; Schønemann-Lund, M; Thornberg Kyhnauv, P; Toft Boesen, HC; Uslu, B; Weber, SO; Westergaard, B; Wetterslev, J, 2022) |
| "To examine the association between the anticholinergic burden (ACB) and the duration and severity of delirium in older hip-surgery patients with or without haloperidol prophylaxis." | 9.41 | The effect of the anticholinergic burden on duration and severity of delirium in older hip-surgery patients with and without haloperidol prophylaxis: A post hoc analysis. ( Butterhoff-Terlingen, MH; Egberts, TCG; Kalisvaart, KJ; Stuffken, R; Tillemans, MPH; Vreeswijk, R, 2021) |
| "None of the three study arms - haloperidol, ketamine, or both drugs combined - was significantly superior to placebo for prevention of postoperative brain dysfunction and delirium (P = 0." | 9.41 | Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. ( Brügger, J; Gysi, B; Hollinger, A; Huber, J; Rentsch, K; Riegger, H; Rüst, CA; Schmid, HR; Siegemund, M; Steiner, L; Surbeck, M; Toft, K; Tran, F, 2021) |
| "Treatment of delirium often includes haloperidol." | 9.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "A preplanned secondary analysis of long-term outcomes of the pRophylactic haloperidol usE for DeliriUm in iCu patients at high risk for dElirium (REDUCE) study was conducted." | 9.30 | Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study. ( Beishuizen, A; Pickkers, P; Rood, PJT; Simons, KS; Slooter, AJC; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PHJ; van der Woude, MCE; Zegers, M, 2019) |
| "AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo." | 9.30 | Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Caballero, J; Citerio, G; Dey, N; Ebdrup, BH; Estrup, S; Hästbacka, J; Hildebrandt, T; Jensen, TB; Lange, T; Mathiesen, O; Morgan, MPG; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Thee, C; Weber, SO; Wetterslev, J; Zafrani, L, 2019) |
| "because the few randomised placebo-controlled trials investigating the potential role for prophylactic haloperidol in delirium prevention have focused on specific surgical populations, we investigated its efficacy and safety in acutely hospitalised older patients." | 9.27 | Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial. ( Anten, S; Bet, PM; Bloemers, FW; Boelaarts, L; de Vries, OJ; Diepeveen, SHA; Kamper, AM; Kramer, MHH; Lagaay, AM; Nanayakkara, PWB; Schrijver, EJM; van de Ven, PM; van Marum, RJ; van Strien, AM, 2018) |
| "Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium." | 9.27 | Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. ( Beishuizen, A; Besselink, A; Brüggemann, RJM; de Koning, J; Dennesen, PJW; Donker, DW; Fuchs, M; Hannink, G; Hofstra, LS; Houterman, S; Karakus, A; Koeman, M; Pickkers, P; Pretorius, D; Schoonhoven, L; Simons, KS; Slooter, AJC; Spronk, PE; van den Bergh, W; van den Boogaard, M; van der Hoeven, JG; Van der Voort, PHJ; van Duijnhoven, M; Vermeijden, JW, 2018) |
| "The Baden PRIDe Trial is an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial for the prevention of delirium with haloperidol, ketamine, and the combination of both vs." | 9.27 | Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium. ( Blum, A; Hollinger, A; Riegger, H; Seifert, B; Siegemund, M; Toft, K; Zehnder, T, 2018) |
| "In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo." | 9.27 | Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. ( Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL, 2018) |
| "To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer." | 9.24 | Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017) |
| "The aim of this study was to evaluate the safety and efficacy of the early administration haloperidol in preventing the aggravation of postoperative delirium in elderly patients." | 9.24 | Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujishiro, K; Fukata, S; Hattori, H; Kawabata, Y; Kitagawa, Y; Kuroiwa, K; Takemura, M, 2017) |
| "To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care." | 9.24 | Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. ( Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C, 2017) |
| "To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3)." | 9.22 | Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016) |
| "To evaluate the clinical effectiveness, safety, and cost of dexmedetomidine for the treatment of agitated delirium refractory to haloperidol in nonintubated critically ill patients." | 9.22 | Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. ( Baeza, N; Cabré, L; Calizaya, M; Carrasco, G; Gimeno, G; Manzanedo, D; Portillo, E, 2016) |
| " One hundred and seventeen adult patients undergoing cardiac surgery were included before introduction of a screening and treatment protocol with haloperidol for delirium, and 123 patients were included after." | 9.19 | Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study. ( Balslev Jørgensen, M; Kirkegaard, T; Lind Jørgensen, V; Schrøder Pedersen, S, 2014) |
| "The preventive administration of low-dose haloperidol did not induce any adverse events, but also did not significantly decrease the incidence or severity of postoperative delirium or shorten its persistence." | 9.19 | Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujisiro, K; Fukata, S; Hattori, H; Katagawa, Y; Kawabata, Y; Kawamura, T; Kuroiwa, K; Terabe, Y, 2014) |
| "The HARPOON study will provide relevant information on the efficacy and safety of prophylactic haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk medical and surgical patients." | 9.19 | Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control ( Anten, S; Bet, PM; Boelaarts, L; de Graaf, K; de Vries, OJ; Diepeveen, SH; Kamper, AM; Kramer, MH; Kuipéri, E; Lagaay, AM; Nanayakkara, PW; Pons, D; Schrijver, EJ; Siegel, A; van de Ven, PM; van Marum, RJ; van Strien, AM; Verburg, A, 2014) |
| "Patients were randomized into 2 groups; in group 1, patients received 5mg of haloperidol intramuscularly and in group 2, patients received 5mg of morphine sulfate intramuscularly to control delirium symptoms." | 9.17 | Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. ( Akgün, S; Atalan, N; Başaran, C; Efe Sevim, M; Fazlıoğulları, O, 2013) |
| "Low-dose quetiapine and haloperidol may be equally effective and safe for controlling delirium symptoms." | 9.17 | Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. ( Chittawatanarat, K; Maneeton, B; Maneeton, N; Srisurapanont, M, 2013) |
| "This will be the first large-scale multicenter randomized controlled prevention study with haloperidol in ICU patients with a high risk of delirium, adequately powered to demonstrate an effect on 28-day survival." | 9.17 | Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. ( Beishuizen, A; Brüggemann, RJ; Hoogendoorn, ME; Houterman, S; Kuiper, MA; Pickkers, P; Schoonhoven, L; Schouten, JA; Slooter, AJ; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PH, 2013) |
| "These results do not support the hypothesis that haloperidol modifies duration of delirium in critically ill patients." | 9.17 | Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. ( Alce, T; Ely, EW; Gates, S; Jackson, J; McAuley, DF; Page, VJ; Perkins, GD; Shintani, A; Zhao, XB, 2013) |
| "This study was a before/after evaluation of a delirium prevention project using prophylactic treatment with haloperidol." | 9.17 | Haloperidol prophylaxis in critically ill patients with a high risk for delirium. ( Pickkers, P; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, JG, 2013) |
| "To evaluate the efficacy and safety of short-term low-dose intravenous haloperidol for delirium prevention in critically ill elderly patients after noncardiac surgery." | 9.16 | Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*. ( Chen, KS; Gu, XE; Li, HL; Li, SL; Wang, DX; Wang, W; Yao, GQ; Zhu, SN; Zhu, X, 2012) |
| "To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium." | 9.16 | Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study. ( Daskalopoulos, ME; Gogaki, E; Papaliagkas, V; Parisis, C; Sataitidis, I; Tagarakis, GI; Tsagalas, I; Tsilimingas, NB; Tsolaki, F; Tsolaki, M; Voucharas, C, 2012) |
| " haloperidol in patients of delirium admitted to medical and surgical wards." | 9.15 | Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. ( Chakrabarti, S; Grover, S; Kumar, V, 2011) |
| "Although a sample size of 440 patients was planned, after inclusion of 104 patients with delirium who were eligible for the intention-to-treat analysis (n=54 on rivastigmine, n=50 on placebo), the DSMB recommended that the trial be halted because mortality in the rivastigmine group (n=12, 22%) was higher than in the placebo group (n=4, 8%; p=0·07)." | 9.14 | Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. ( Honing, ML; Karakus, A; Kesecioglu, J; Kuiper, MA; Roes, KC; Slooter, AJ; Spronk, PE; van der Jagt, M; van der Mast, RC; van Eijk, MM; van Gool, WA, 2010) |
| " The prophylactic use of haloperidol did not reduce the delirium incidence (RR: 0." | 9.12 | Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis. ( Buonanno, P; Iacovazzo, C; Kotfis, K; Marra, A; Servillo, G; Vargas, M, 2021) |
| "To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting." | 9.11 | Olanzapine vs haloperidol: treating delirium in a critical care setting. ( Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK, 2004) |
| "To study the effectiveness of haloperidol prophylaxis on incidence, severity, and duration of postoperative delirium in elderly hip-surgery patients at risk for delirium." | 9.11 | Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. ( Bogaards, MJ; Burger, BJ; de Jonghe, JF; Egberts, TC; Eikelenboom, P; Kalisvaart, KJ; van Gool, WA; Vreeswijk, R, 2005) |
| "The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial." | 9.08 | A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996) |
| "Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage." | 9.08 | Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996) |
| "Sixty-six patients (47 men, 19 women, mean age 65 years) with delirium were treated with mianserin (10-60 mg/day) or haloperidol (2-6 mg/day) at Kurume University Hospital." | 9.08 | Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1997) |
| "Mianserin (10-60 mg), haloperidol (2-6 mg) and oxypertine (20-60 mg) were administered once before bedtime in patients with delirium in Kurume University Hospital." | 9.07 | [Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol]. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1994) |
| "Haloperidol is the most frequently used drug to treat delirium in the critically ill patients." | 9.05 | Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis. ( Andersen-Ranberg, NC; Barbateskovic, M; Collet, MO; Jakobsen, JC; Krauss, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2020) |
| "To identify the efficacy and safety of haloperidol prophylaxis in adult patients with a high risk for delirium." | 9.05 | Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials. ( Chen, R; Chen, Z; Deng, Y; Guo, H; Hou, Y; Liu, G; Su, Y; Wei, X; Wen, S; Ye, Z; Zheng, D; Zuo, L, 2020) |
| "Our study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium." | 9.01 | Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. ( Aburahma, A; Bachuwa, G; Banifadel, M; Barbarawi, M; Chahine, A; Haykal, T; Kheiri, B; Rashdan, L; Seedahmed, E; Zayed, Y, 2019) |
| "Our ambition with this systematic review is to provide reliable and powered evidence to better inform decision makers on the use of or future trials with haloperidol for the management of delirium in critically ill patients." | 8.98 | Haloperidol for delirium in critically ill patients - protocol for a systematic review. ( Barbateskovic, M; Collet, MO; Jakobsen, JC; Kraus, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2018) |
| "The aim of this systematic review and meta-analysis was to investigate whether or not the use of haloperidol could reduce the incidence of delirium in adult patients." | 8.98 | Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis. ( Ji, FH; Meng, XW; Peng, K; Shen, YZ; Zhang, J, 2018) |
| "To identify the effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium." | 8.95 | Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. ( Apóstolo, J; Cardoso, D; Cunha, M; Neves, H; Rodrigues, M; Santos, E, 2017) |
| "Haloperidol is generally considered the drug of choice for in-hospital delirium management." | 8.93 | Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence. ( de Graaf, K; de Vries, OJ; Maier, AB; Nanayakkara, PW; Schrijver, EJ, 2016) |
| "Adjunctive low-dose haloperidol prophylaxis reduces delirium severity, duration, and subsequent hospitalization length in elderly at-risk patients." | 8.84 | Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. ( Caselli, RJ; Demaerschalk, BM; Schrader, SL; Wellik, KE; Wingerchuk, DM; Woodruff, BK, 2008) |
| "Intravenous haloperidol is the agent of choice for controlling severe agitated delirium in seriously ill cardiac patients in many institutions." | 8.79 | Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. ( Di Salvo, TG; O'Gara, PT, 1995) |
| "Delirium is a common distressing symptom observed in patients with terminal respiratory diseases and is treated with antipsychotic medications such as haloperidol." | 8.31 | Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases. ( Ando, K; Suzuki, A; Yoshida, H, 2023) |
| "Haloperidol is frequently used as first-line treatment for delirium." | 8.31 | [Haloperidol is not the first choice for every case of delirium]. ( Aebischer, O; Charlier, C; Jaren, L, 2023) |
| "For the treatment of delirium, antipsychotics such as haloperidol are used as standard treatments." | 8.12 | A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium. ( Sato, J; Tanaka, R, 2022) |
| "Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium." | 8.02 | Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. ( Dijkstra-Kersten, SMA; Slooter, AJC; Smit, L; van der Jagt, M; Zaal, IJ, 2021) |
| "The aim of this study was to evaluate outcomes of pediatric intensive care unit (PICU) patients with delirium treated with haloperidol or quetiapine compared with propensity-matched, untreated patients." | 8.02 | Haloperidol and Quetiapine for the Treatment of ICU-Associated Delirium in a Tertiary Pediatric ICU: A Propensity Score-Matched Cohort Study. ( Cronin, MT; Dervan, LA; Di Gennaro, JL; Watson, RS, 2021) |
| "Haloperidol is commonly administered in the ICU to reduce the burden of delirium and its related symptoms despite no clear evidence showing haloperidol helps to resolve delirium or improve survival." | 8.02 | Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. ( Briesacher, BA; Devlin, JW; Duprey, MS; Griffith, JL; Pickkers, P; Saczynski, JS; van den Boogaard, M; van der Hoeven, JG, 2021) |
| "To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults." | 7.96 | Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. ( Devlin, JW; Hunfeld, NGM; Koch, BCP; Nieboer, D; Osse, RJ; Trogrlić, Z; van der Jagt, M; van Schaik, RHN, 2020) |
| "As delirium in critically ill children is increasingly recognized, more children are treated with the antipsychotic drug haloperidol, while current dosing guidelines are lacking solid evidence and appear to be associated with a high risk of adverse events." | 7.88 | Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. ( de Wildt, SN; Ista, E; Jessurun, N; Slooff, VD; Tibboel, D; van Beusekom, BS; van den Dungen, DK, 2018) |
| "We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality." | 7.88 | Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study. ( Barbateskovic, M; Bozza, FA; Caballero, J; Citerio, G; Collet, MO; Colpaert, K; Egerod, I; Haenggi, M; Hästbacka, J; Jensen, A; Krog, MB; Lange, T; Nibro, HL; Nydahl, P; Perner, A; Rose, L; Schandl, A; Sonneville, R; van den Boogaard, M; Wetterslev, J; Wøien, H, 2018) |
| "In this retrospective, descriptive cohort study of 192 patients, pipamperone as monotherapy and as an adjunct to haloperidol, haloperidol alone, or atypical antipsychotics were compared with respect to their effectiveness in the management of delirium and its subtypes over the course of 20 days." | 7.85 | Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes. ( Boettger, S; Garcia Nuñez, D; Jenewein, J; Klaghofer, R; Knöpfel, S; Plichta, MM; Schubert, M, 2017) |
| " Dexmedetomidine significantly decreased the ICU LOS and ICU LOS after the occurrence of delirium compared to haloperidol (13." | 7.83 | Use of Dexmedetomidine in Liver Transplant Recipients With Postoperative Agitated Delirium. ( Choi, JY; Gwak, MS; Joh, JW; Kim, GS; Kim, JM; Kim, SJ; Ko, JS; Kwon, CH; Lee, S; Lee, SK; Park, JB, 2016) |
| "The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium." | 7.81 | Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015) |
| "To evaluate the association between cumulative dose of haloperidol and next-day diagnosis of delirium in a cohort of older medical ICU patients, with adjustment for its time-dependent confounding with fentanyl and intubation." | 7.81 | Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. ( Araujo, KL; Murphy, TE; Pisani, MA, 2015) |
| "Practice guidelines recommend the use of low dose haloperidol when medication is needed to treat delirium with acute agitation in hospitalized older people." | 7.79 | Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. ( Dorokhine, I; Knapp, CM; Musuku, M; Patel, N; Zirker, W, 2013) |
| "This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital." | 7.79 | Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. ( Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013) |
| " Haloperidol, a butyrophenone derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care." | 7.79 | Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. ( Agar M, M; Crawford, GB; Currow, DC; Doogue, M; Litster, C; Michael, N; Phillips, J; Quinn, SJ; Rowett, D, 2013) |
| "To compare the efficacy and tolerability of aripiprazole and haloperidol in the amelioration of distressing symptoms of delirium and its motoric subtypes." | 7.77 | Aripiprazole and haloperidol in the treatment of delirium. ( Boettger, S; Breitbart, W; Friedlander, M; Passik, S, 2011) |
| " We measured CAM-ICU compliance, interrater reliability, and delirium knowledge, and compared the haloperidol use, as a proxy for delirium incidence, before and after the implementation of the CAM-ICU." | 7.75 | Implementation of a delirium assessment tool in the ICU can influence haloperidol use. ( Pickkers, P; Roodbol, G; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, H, 2009) |
| "The aim of this study was to determine the risk of adverse events for risperidone and haloperidol in delirium patients." | 7.74 | Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. ( Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K, 2007) |
| "The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life." | 7.11 | An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. ( Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ, 2022) |
| "Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects." | 6.48 | Haloperidol dosing strategies in the treatment of delirium in the critically ill. ( Ensom, MH; Loh, GW; Mabasa, VH; Wang, EH, 2012) |
| "Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated." | 6.44 | Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. ( Battistone, S; Devlin, JW; Fong, JJ; Rea, RS, 2007) |
| "The AID-ICU trial was a randomised, blinded, placebo-controlled trial investigating effects of haloperidol versus placebo in acutely admitted, adult patients admitted in intensive care unit (ICU) with delirium." | 5.69 | Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Citerio, G; Collet, MO; Damgaard, K; Dey, N; Granholm, A; Hästbacka, J; Jensen, TB; Mathiesen, O; Morgan, M; Nielsen, LG; Pedersen, HS; Perner, A; Poulsen, LM; Sommer, T; Uslu, B; Weber, SO, 2023) |
| "This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital." | 5.69 | Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023) |
| "The role of haloperidol as treatment for ICU delirium and related symptoms remains controversial despite two recent large controlled trials evaluating its efficacy and safety." | 5.69 | Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. ( Boer, DP; Brouwers, AJBW; Devlin, JW; Gommers, DAMPJ; Hunfeld, NGM; Lens, JA; Osse, RJ; Ponssen, HH; Rietdijk, WJR; Schoonderbeek, JF; Simons, KS; Slooter, AJC; Smit, L; Trogrlic, Z; van den Boogaard, M; van der Jagt, M, 2023) |
| "Haloperidol is frequently used to treat delirium in patients in the intensive care unit (ICU), but evidence of its effect is limited." | 5.51 | Haloperidol for the Treatment of Delirium in ICU Patients. ( Aagaard, SR; Andersen-Ranberg, NC; Andreasen, AS; Bestle, MH; Brand, B; Brix, H; Caballero, J; Citerio, G; de Haas, I; Ebdrup, BH; Engstrøm, J; Eriksen, AS; Estrup, S; Fjeldsøe-Nielsen, H; Gramstrup Nielsen, L; Hästbacka, J; Haurum, C; Hildebrandt, T; Hyttel-Sørensen, S; Jensen, JV; Kingo Vesterlund, G; Kjær, MN; Kuivalainen, AM; La Cour, K; Laigaard, J; Lange, T; Mathiesen, O; Mikkelsen, VS; Morgan, M; Mortensen, CB; Nebrich, L; Nielsen, LO; Olesen, MW; Olsen, MH; Overgaard-Steensen, C; Oxenbøll Collet, M; Perner, A; Poulsen, LM; Rasmussen, BS; Scharling Pedersen, H; Schønemann-Lund, M; Thornberg Kyhnauv, P; Toft Boesen, HC; Uslu, B; Weber, SO; Westergaard, B; Wetterslev, J, 2022) |
| "To examine the association between the anticholinergic burden (ACB) and the duration and severity of delirium in older hip-surgery patients with or without haloperidol prophylaxis." | 5.41 | The effect of the anticholinergic burden on duration and severity of delirium in older hip-surgery patients with and without haloperidol prophylaxis: A post hoc analysis. ( Butterhoff-Terlingen, MH; Egberts, TCG; Kalisvaart, KJ; Stuffken, R; Tillemans, MPH; Vreeswijk, R, 2021) |
| " Meta-analyses and GRADE level of evidence ratings show no increased delirium risk for Haloperidol (OR: 0." | 5.41 | Delirium-associated medication in people at risk: A systematic update review, meta-analyses, and GRADE-profiles. ( Biasi, J; Fellendorf, FT; Reininghaus, EZ; Reisinger, M; Schoberer, D, 2023) |
| "None of the three study arms - haloperidol, ketamine, or both drugs combined - was significantly superior to placebo for prevention of postoperative brain dysfunction and delirium (P = 0." | 5.41 | Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. ( Brügger, J; Gysi, B; Hollinger, A; Huber, J; Rentsch, K; Riegger, H; Rüst, CA; Schmid, HR; Siegemund, M; Steiner, L; Surbeck, M; Toft, K; Tran, F, 2021) |
| "This was a pre-planned secondary analysis of a double-blind, randomized clinical trial comparing the use of a single dose of lorazepam plus haloperidol versus placebo plus haloperidol in patients with agitated delirium." | 5.41 | Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium. ( Bruera, E; Chen, M; Hui, D; Tang, M, 2021) |
| "This was a preplanned secondary analysis of a double-blind randomized clinical trial examining the sedative effect of chlorpromazine and/or haloperidol in patients with agitated delirium." | 5.41 | Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication. ( Bruera, E; De La Rosa, A; Hui, D; Nguyen, T; Urbauer, DL, 2021) |
| "Haloperidol was initiated at 5 mg intravenous every 6 h and titrated up to a dose of 60 mg /day over 5 days." | 5.39 | Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? ( Adelman, M; Dixit, D; Shrestha, P, 2013) |
| "Treatment of delirium often includes haloperidol." | 5.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "The AID-ICU trial aims to assess the benefits and harms of haloperidol for the treatment of delirium in acutely admitted, adult intensive care unit (ICU) patients." | 5.34 | The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan. ( Andersen-Ranberg, N; Bestle, MH; Caballero, J; Citerio, G; Dey, N; Ebdrup, BH; Estrup, S; Hästbacka, J; Jensen, TB; Lange, T; Mathiesen, O; Morgan, MPG; Mortensen, CB; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Sofie Andreasen, A; Thee, C; Uslu, B; Weber, SO; Wetterslev, J, 2020) |
| "Therefore treatment of delirium with a cholinesterase-inhibitor seems logical." | 5.32 | [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]. ( Boelaarts, L; de Jonghe, JF; Hovinga, IM; Kalisvaart, CJ; Kat, MG, 2004) |
| "A new delirium was induced when, after discharge from the hospital, betahistine was restarted because of dizziness." | 5.32 | [Delirium in a 73-year-old man after many years of unwise use of betahistine]. ( Hoenders, HJ; Wilterdink, J, 2004) |
| "A preplanned secondary analysis of long-term outcomes of the pRophylactic haloperidol usE for DeliriUm in iCu patients at high risk for dElirium (REDUCE) study was conducted." | 5.30 | Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study. ( Beishuizen, A; Pickkers, P; Rood, PJT; Simons, KS; Slooter, AJC; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PHJ; van der Woude, MCE; Zegers, M, 2019) |
| "AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo." | 5.30 | Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Caballero, J; Citerio, G; Dey, N; Ebdrup, BH; Estrup, S; Hästbacka, J; Hildebrandt, T; Jensen, TB; Lange, T; Mathiesen, O; Morgan, MPG; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Thee, C; Weber, SO; Wetterslev, J; Zafrani, L, 2019) |
| "because the few randomised placebo-controlled trials investigating the potential role for prophylactic haloperidol in delirium prevention have focused on specific surgical populations, we investigated its efficacy and safety in acutely hospitalised older patients." | 5.27 | Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial. ( Anten, S; Bet, PM; Bloemers, FW; Boelaarts, L; de Vries, OJ; Diepeveen, SHA; Kamper, AM; Kramer, MHH; Lagaay, AM; Nanayakkara, PWB; Schrijver, EJM; van de Ven, PM; van Marum, RJ; van Strien, AM, 2018) |
| "Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium." | 5.27 | Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. ( Beishuizen, A; Besselink, A; Brüggemann, RJM; de Koning, J; Dennesen, PJW; Donker, DW; Fuchs, M; Hannink, G; Hofstra, LS; Houterman, S; Karakus, A; Koeman, M; Pickkers, P; Pretorius, D; Schoonhoven, L; Simons, KS; Slooter, AJC; Spronk, PE; van den Bergh, W; van den Boogaard, M; van der Hoeven, JG; Van der Voort, PHJ; van Duijnhoven, M; Vermeijden, JW, 2018) |
| "The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium." | 5.27 | The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. ( Arthur, J; Bruera, E; Dalal, S; Dev, R; Dibaj, SS; Hess, K; Hui, D; Reddy, S, 2018) |
| "The Baden PRIDe Trial is an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial for the prevention of delirium with haloperidol, ketamine, and the combination of both vs." | 5.27 | Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium. ( Blum, A; Hollinger, A; Riegger, H; Seifert, B; Siegemund, M; Toft, K; Zehnder, T, 2018) |
| "In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo." | 5.27 | Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. ( Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL, 2018) |
| "To assess the efficacy of haloperidol in reducing postoperative delirium in individuals undergoing thoracic surgery." | 5.27 | Preventing Postoperative Delirium After Major Noncardiac Thoracic Surgery-A Randomized Clinical Trial. ( Boustani, MA; Campbell, NL; Fuchita, M; Gao, S; Kesler, K; Khan, BA; Khan, SH; Perkins, AJ; Wang, S; Weber, DJ; Zarzaur, BL, 2018) |
| "To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer." | 5.24 | Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017) |
| "The aim of this study was to evaluate the safety and efficacy of the early administration haloperidol in preventing the aggravation of postoperative delirium in elderly patients." | 5.24 | Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujishiro, K; Fukata, S; Hattori, H; Kawabata, Y; Kitagawa, Y; Kuroiwa, K; Takemura, M, 2017) |
| "To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care." | 5.24 | Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. ( Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C, 2017) |
| "To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3)." | 5.22 | Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016) |
| "To evaluate the clinical effectiveness, safety, and cost of dexmedetomidine for the treatment of agitated delirium refractory to haloperidol in nonintubated critically ill patients." | 5.22 | Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. ( Baeza, N; Cabré, L; Calizaya, M; Carrasco, G; Gimeno, G; Manzanedo, D; Portillo, E, 2016) |
| "Patients enrolled in a randomized controlled clinical trial of melatonin versus placebo on occurrence of delirium in hip-fracture patients." | 5.20 | In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration. ( Blom, MT; de Boer, A; de Jonghe, A; de Rooij, SE; Jansen, S; Tan, HL; van der Velde, N; van Munster, BC, 2015) |
| " One hundred and seventeen adult patients undergoing cardiac surgery were included before introduction of a screening and treatment protocol with haloperidol for delirium, and 123 patients were included after." | 5.19 | Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study. ( Balslev Jørgensen, M; Kirkegaard, T; Lind Jørgensen, V; Schrøder Pedersen, S, 2014) |
| "The preventive administration of low-dose haloperidol did not induce any adverse events, but also did not significantly decrease the incidence or severity of postoperative delirium or shorten its persistence." | 5.19 | Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujisiro, K; Fukata, S; Hattori, H; Katagawa, Y; Kawabata, Y; Kawamura, T; Kuroiwa, K; Terabe, Y, 2014) |
| "The HARPOON study will provide relevant information on the efficacy and safety of prophylactic haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk medical and surgical patients." | 5.19 | Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control ( Anten, S; Bet, PM; Boelaarts, L; de Graaf, K; de Vries, OJ; Diepeveen, SH; Kamper, AM; Kramer, MH; Kuipéri, E; Lagaay, AM; Nanayakkara, PW; Pons, D; Schrijver, EJ; Siegel, A; van de Ven, PM; van Marum, RJ; van Strien, AM; Verburg, A, 2014) |
| "Patients were randomized into 2 groups; in group 1, patients received 5mg of haloperidol intramuscularly and in group 2, patients received 5mg of morphine sulfate intramuscularly to control delirium symptoms." | 5.17 | Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. ( Akgün, S; Atalan, N; Başaran, C; Efe Sevim, M; Fazlıoğulları, O, 2013) |
| "Low-dose quetiapine and haloperidol may be equally effective and safe for controlling delirium symptoms." | 5.17 | Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. ( Chittawatanarat, K; Maneeton, B; Maneeton, N; Srisurapanont, M, 2013) |
| "This will be the first large-scale multicenter randomized controlled prevention study with haloperidol in ICU patients with a high risk of delirium, adequately powered to demonstrate an effect on 28-day survival." | 5.17 | Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. ( Beishuizen, A; Brüggemann, RJ; Hoogendoorn, ME; Houterman, S; Kuiper, MA; Pickkers, P; Schoonhoven, L; Schouten, JA; Slooter, AJ; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PH, 2013) |
| "These results do not support the hypothesis that haloperidol modifies duration of delirium in critically ill patients." | 5.17 | Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. ( Alce, T; Ely, EW; Gates, S; Jackson, J; McAuley, DF; Page, VJ; Perkins, GD; Shintani, A; Zhao, XB, 2013) |
| "This study was a before/after evaluation of a delirium prevention project using prophylactic treatment with haloperidol." | 5.17 | Haloperidol prophylaxis in critically ill patients with a high risk for delirium. ( Pickkers, P; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, JG, 2013) |
| "To evaluate the efficacy and safety of short-term low-dose intravenous haloperidol for delirium prevention in critically ill elderly patients after noncardiac surgery." | 5.16 | Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*. ( Chen, KS; Gu, XE; Li, HL; Li, SL; Wang, DX; Wang, W; Yao, GQ; Zhu, SN; Zhu, X, 2012) |
| "To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium." | 5.16 | Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study. ( Daskalopoulos, ME; Gogaki, E; Papaliagkas, V; Parisis, C; Sataitidis, I; Tagarakis, GI; Tsagalas, I; Tsilimingas, NB; Tsolaki, F; Tsolaki, M; Voucharas, C, 2012) |
| " haloperidol in patients of delirium admitted to medical and surgical wards." | 5.15 | Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. ( Chakrabarti, S; Grover, S; Kumar, V, 2011) |
| "Agitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy." | 5.14 | Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. ( Ainslie, WR; Bates, S; Bellomo, R; Goldsmith, D; O'Sullivan, K; Reade, MC, 2009) |
| "To compare the efficacy and safety of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol." | 5.14 | Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. ( Devlin, JW; Fong, JJ; Garpestad, E; Hill, NS; Riker, RR; Robbins, T; Roberts, RJ; Skrobik, Y, 2010) |
| "Although a sample size of 440 patients was planned, after inclusion of 104 patients with delirium who were eligible for the intention-to-treat analysis (n=54 on rivastigmine, n=50 on placebo), the DSMB recommended that the trial be halted because mortality in the rivastigmine group (n=12, 22%) was higher than in the placebo group (n=4, 8%; p=0·07)." | 5.14 | Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. ( Honing, ML; Karakus, A; Kesecioglu, J; Kuiper, MA; Roes, KC; Slooter, AJ; Spronk, PE; van der Jagt, M; van der Mast, RC; van Eijk, MM; van Gool, WA, 2010) |
| " Hip surgery patients (n = 112) aged 70 years and older, who participated in a controlled clinical trial of haloperidol prophylaxis for delirium, were followed for an average of 30 months after discharge." | 5.13 | Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. ( de Jonghe, JF; Eikelenboom, P; Kalisvaart, KJ; Kat, MG; van der Ploeg, T; van Gool, WA; Vreeswijk, R, 2008) |
| " The prophylactic use of haloperidol did not reduce the delirium incidence (RR: 0." | 5.12 | Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis. ( Buonanno, P; Iacovazzo, C; Kotfis, K; Marra, A; Servillo, G; Vargas, M, 2021) |
| "To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting." | 5.11 | Olanzapine vs haloperidol: treating delirium in a critical care setting. ( Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK, 2004) |
| "To study the effectiveness of haloperidol prophylaxis on incidence, severity, and duration of postoperative delirium in elderly hip-surgery patients at risk for delirium." | 5.11 | Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. ( Bogaards, MJ; Burger, BJ; de Jonghe, JF; Egberts, TC; Eikelenboom, P; Kalisvaart, KJ; van Gool, WA; Vreeswijk, R, 2005) |
| "The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial." | 5.08 | A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996) |
| "Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage." | 5.08 | Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996) |
| "Sixty-six patients (47 men, 19 women, mean age 65 years) with delirium were treated with mianserin (10-60 mg/day) or haloperidol (2-6 mg/day) at Kurume University Hospital." | 5.08 | Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1997) |
| "Mianserin (10-60 mg), haloperidol (2-6 mg) and oxypertine (20-60 mg) were administered once before bedtime in patients with delirium in Kurume University Hospital." | 5.07 | [Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol]. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1994) |
| "Haloperidol is the most frequently used drug to treat delirium in the critically ill patients." | 5.05 | Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis. ( Andersen-Ranberg, NC; Barbateskovic, M; Collet, MO; Jakobsen, JC; Krauss, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2020) |
| "To identify the efficacy and safety of haloperidol prophylaxis in adult patients with a high risk for delirium." | 5.05 | Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials. ( Chen, R; Chen, Z; Deng, Y; Guo, H; Hou, Y; Liu, G; Su, Y; Wei, X; Wen, S; Ye, Z; Zheng, D; Zuo, L, 2020) |
| " All of the participants had delirium, were treated with haloperidol, and were randomised to receive either lorazepam or placebo in combination with it." | 5.05 | Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit. ( Chen, J; Jin, Y; Li, N; Li, Y; Ma, J; Mu, W; Shang, HC; Si, JH; Wang, J; Zheng, R, 2020) |
| "Across 16 RCTs and 10 observational studies of hospitalized adults, there was no difference in sedation status (low and moderate SOE), delirium duration, hospital length of stay (moderate SOE), or mortality between haloperidol and second-generation antipsychotics versus placebo." | 5.01 | Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. ( Needham, DM; Neufeld, KJ; Nikooie, R; Oh, ES; Robinson, KA; Wilson, LM; Zhang, A, 2019) |
| " There were no differences in delirium incidence or duration, hospital length of stay (high strength of evidence [SOE]), and mortality between haloperidol and placebo used for delirium prevention." | 5.01 | Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review. ( Needham, DM; Neufeld, KJ; Nikooie, R; Oh, ES; Robinson, KA; Wilson, LM; Zhang, A, 2019) |
| "Our study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium." | 5.01 | Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. ( Aburahma, A; Bachuwa, G; Banifadel, M; Barbarawi, M; Chahine, A; Haykal, T; Kheiri, B; Rashdan, L; Seedahmed, E; Zayed, Y, 2019) |
| "This network meta-analysis demonstrated that haloperidol plus lorazepam might be the best treatment and ramelteon the best preventive medicine for delirium." | 5.01 | Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis. ( Carvalho, AF; Chen, TY; Chen, YW; Chu, CS; Hsu, CY; Liang, CS; Lin, PY; Matsuoka, YJ; Stubbs, B; Su, KP; Tseng, PT; Tu, YK; Wada, S; Wu, YC; Yeh, TC, 2019) |
| "Our ambition with this systematic review is to provide reliable and powered evidence to better inform decision makers on the use of or future trials with haloperidol for the management of delirium in critically ill patients." | 4.98 | Haloperidol for delirium in critically ill patients - protocol for a systematic review. ( Barbateskovic, M; Collet, MO; Jakobsen, JC; Kraus, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2018) |
| "The aim of this systematic review and meta-analysis was to investigate whether or not the use of haloperidol could reduce the incidence of delirium in adult patients." | 4.98 | Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis. ( Ji, FH; Meng, XW; Peng, K; Shen, YZ; Zhang, J, 2018) |
| "There is probably little or no difference between haloperidol and placebo for preventing ICU delirium but further studies are needed to increase our confidence in the findings." | 4.98 | Interventions for preventing intensive care unit delirium in adults. ( Bekker Mortensen, C; Egerod, I; Greve, IE; Herling, SF; Møller, AM; Svenningsen, H; Thomsen, T; Vasilevskis, EE, 2018) |
| "To identify the effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium." | 4.95 | Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. ( Apóstolo, J; Cardoso, D; Cunha, M; Neves, H; Rodrigues, M; Santos, E, 2017) |
| "Haloperidol is generally considered the drug of choice for in-hospital delirium management." | 4.93 | Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence. ( de Graaf, K; de Vries, OJ; Maier, AB; Nanayakkara, PW; Schrijver, EJ, 2016) |
| "The use of antipsychotics for surgical ICU patients and dexmedetomidine for mechanically ventilated patients as a preventive strategy may reduce the prevalence of delirium in the ICU." | 4.91 | Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. ( Bozza, FA; do Brasil, PE; Ely, EW; Salluh, JI; Serafim, RB; Soares, M; Tura, BR, 2015) |
| "Haloperidol (HP) is used for the symptomatic treatment of psychosis, manic phases, hyperactivity, aggressiveness, and acute delirium." | 4.89 | Haloperidol cytotoxicity and its relation to oxidative stress. ( Adam, V; Babula, P; Gumulec, J; Kizek, R; Masarik, M; Novakova, M; Polanska, H; Raudenska, M; Stracina, T; Sztalmachova, M, 2013) |
| "The existing limited data indicates no superiority for second-generation antipsychotics over haloperidol in managing delirium." | 4.85 | Pharmacological management of delirium in hospitalized adults--a systematic evidence review. ( Ademuyiwa, A; Ayub, A; Boustani, MA; Campbell, N; Farber, M; Fox, GC; Guzman, O; Munger, SL; Ott, C; Singh, R, 2009) |
| "To compare the efficacy and incidence of adverse effects of haloperidol with risperidone, olanzapine, and quetiapine in the treatment of delirium." | 4.84 | Antipsychotics for delirium. ( Britton, AM; Lonergan, E; Luxenberg, J; Wyller, T, 2007) |
| "A review of current literature supports the conclusion that atypical antipsychotic medications demonstrate similar rates of efficacy as haloperidol for the treatment of delirium in the elderly patient, with a lower rate of extrapyramidal side effects." | 4.84 | Atypical antipsychotics for the treatment of delirious elders. ( Kaiser, RM; Ozbolt, LB; Paniagua, MA, 2008) |
| "Adjunctive low-dose haloperidol prophylaxis reduces delirium severity, duration, and subsequent hospitalization length in elderly at-risk patients." | 4.84 | Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. ( Caselli, RJ; Demaerschalk, BM; Schrader, SL; Wellik, KE; Wingerchuk, DM; Woodruff, BK, 2008) |
| "The data from one study of 30 patients would perhaps suggest that haloperidol is the most suitable drug therapy for the treatment of patients with delirium near the end of life." | 4.82 | Drug therapy for delirium in terminally ill patients. ( Jackson, KC; Lipman, AG, 2004) |
| "Intravenous haloperidol is the agent of choice for controlling severe agitated delirium in seriously ill cardiac patients in many institutions." | 4.79 | Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. ( Di Salvo, TG; O'Gara, PT, 1995) |
| "Intravenous haloperidol is recommended as the drug of choice to treat delirium in ICU patients." | 4.79 | Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. ( Fraser, GL; Richen, P; Riker, RR, 1997) |
| "Delirium is a common distressing symptom observed in patients with terminal respiratory diseases and is treated with antipsychotic medications such as haloperidol." | 4.31 | Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases. ( Ando, K; Suzuki, A; Yoshida, H, 2023) |
| "The findings of this cohort study suggest that the discontinuation rate of newly initiated APMs for delirium following infection-related hospitalization was lower in atypical APM users than in haloperidol users, with prolonged hospitalization and dementia as major associated variables." | 4.31 | Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization. ( Bessette, LG; Lin, KJ; Wilkins, JM; Wong, V; York, C; Zhang, Y, 2023) |
| "Haloperidol is frequently used as first-line treatment for delirium." | 4.31 | [Haloperidol is not the first choice for every case of delirium]. ( Aebischer, O; Charlier, C; Jaren, L, 2023) |
| "For the treatment of delirium, antipsychotics such as haloperidol are used as standard treatments." | 4.12 | A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium. ( Sato, J; Tanaka, R, 2022) |
| " Inquiries were made regarding: (i) choice of drug class in the first-line treatment, (ii) administration methods of the first-line antipsychotic treatment, (iii) starting dose of antipsychotics in the first line treatment and maximum dose of antipsychotics in refractory delirium, and (iv) choice of treatment when the first-line haloperidol treatment failed." | 4.12 | Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists. ( Kashiwagi, H; Matsuda, Y; Morita, T; Naito, AS; Otani, H; Oya, K; Tagami, K, 2022) |
| "Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium." | 4.02 | Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. ( Dijkstra-Kersten, SMA; Slooter, AJC; Smit, L; van der Jagt, M; Zaal, IJ, 2021) |
| "The aim of this study was to evaluate outcomes of pediatric intensive care unit (PICU) patients with delirium treated with haloperidol or quetiapine compared with propensity-matched, untreated patients." | 4.02 | Haloperidol and Quetiapine for the Treatment of ICU-Associated Delirium in a Tertiary Pediatric ICU: A Propensity Score-Matched Cohort Study. ( Cronin, MT; Dervan, LA; Di Gennaro, JL; Watson, RS, 2021) |
| "Haloperidol is commonly administered in the ICU to reduce the burden of delirium and its related symptoms despite no clear evidence showing haloperidol helps to resolve delirium or improve survival." | 4.02 | Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. ( Briesacher, BA; Devlin, JW; Duprey, MS; Griffith, JL; Pickkers, P; Saczynski, JS; van den Boogaard, M; van der Hoeven, JG, 2021) |
| "Although extrapyramidal adverse effects are less common with olanzapine than with typical antipsychotics, they sometimes occur and can mimic manifestations of delirium." | 4.02 | Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report. ( Rose, MQ; Santos, CD, 2021) |
| "To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults." | 3.96 | Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. ( Devlin, JW; Hunfeld, NGM; Koch, BCP; Nieboer, D; Osse, RJ; Trogrlić, Z; van der Jagt, M; van Schaik, RHN, 2020) |
| " Patients who showed positive Confusion Assessment Method or received haloperidol within 4 days postoperatively were enrolled as those with postoperative delirium (+)." | 3.88 | Hydroxyethyl starch is associated with early postoperative delirium in patients undergoing esophagectomy. ( Ahn, HJ; Jung, DM; Kim, DK; Kim, JA; Lee, SM; Park, JH; Yang, M, 2018) |
| "As delirium in critically ill children is increasingly recognized, more children are treated with the antipsychotic drug haloperidol, while current dosing guidelines are lacking solid evidence and appear to be associated with a high risk of adverse events." | 3.88 | Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. ( de Wildt, SN; Ista, E; Jessurun, N; Slooff, VD; Tibboel, D; van Beusekom, BS; van den Dungen, DK, 2018) |
| "We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality." | 3.88 | Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study. ( Barbateskovic, M; Bozza, FA; Caballero, J; Citerio, G; Collet, MO; Colpaert, K; Egerod, I; Haenggi, M; Hästbacka, J; Jensen, A; Krog, MB; Lange, T; Nibro, HL; Nydahl, P; Perner, A; Rose, L; Schandl, A; Sonneville, R; van den Boogaard, M; Wetterslev, J; Wøien, H, 2018) |
| " Fentanyl, midazolam, and dexmedetomidine were the first choices of agents for analgesic, sedation, and delirium treatment." | 3.85 | A National Multicenter Survey on Management of Pain, Agitation, and Delirium in Intensive Care Units in China. ( Hu, B; Li, JG; Peng, ZY; Rao, X; Wang, J; Zhou, WH, 2017) |
| "In this retrospective, descriptive cohort study of 192 patients, pipamperone as monotherapy and as an adjunct to haloperidol, haloperidol alone, or atypical antipsychotics were compared with respect to their effectiveness in the management of delirium and its subtypes over the course of 20 days." | 3.85 | Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes. ( Boettger, S; Garcia Nuñez, D; Jenewein, J; Klaghofer, R; Knöpfel, S; Plichta, MM; Schubert, M, 2017) |
| "A patient with bipolar I disorder has been treated with lithium and haloperidol for the last 20 years and received an ACE inhibitor for his hypertension since 9 years ago." | 3.85 | Hypertensive bipolar: chronic lithium toxicity in patients taking ACE inhibitor. ( Abdul Aziz, MF; Masiran, R, 2017) |
| "To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)." | 3.83 | Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016) |
| " The outcome of interest was death within 14 days from commencement of haloperidol treatment for delirium." | 3.83 | Predictors of Mortality for Delirium in Palliative Care. ( Agar, MR; Collier, A; Crawford, GB; Currow, DC; Phillips, JL; Quinn, SJ; Ritchie, CS, 2016) |
| " Dexmedetomidine significantly decreased the ICU LOS and ICU LOS after the occurrence of delirium compared to haloperidol (13." | 3.83 | Use of Dexmedetomidine in Liver Transplant Recipients With Postoperative Agitated Delirium. ( Choi, JY; Gwak, MS; Joh, JW; Kim, GS; Kim, JM; Kim, SJ; Ko, JS; Kwon, CH; Lee, S; Lee, SK; Park, JB, 2016) |
| "The World Health Organization recommends that anxiety, depression, agitation and delirium at end of life should be treated with drugs such as lorazepam, diazepam, midazolam and haloperidol." | 3.83 | Look again at psychedelic drugs. ( Cameron, R, 2016) |
| "The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium." | 3.81 | Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015) |
| "To evaluate the association between cumulative dose of haloperidol and next-day diagnosis of delirium in a cohort of older medical ICU patients, with adjustment for its time-dependent confounding with fentanyl and intubation." | 3.81 | Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. ( Araujo, KL; Murphy, TE; Pisani, MA, 2015) |
| "Completion of a survey containing 10 hypothetical ICU cases in which patients had agitated delirium for which a psychiatrist recommended intravenous haloperidol 5 mg every 6 hours." | 3.79 | Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. ( Al-Qadheeb, NS; Devlin, JW; Estes, NA; Fongemie, JM; Roberts, RJ; Ruthazer, R; Temtanakitpaisan, Y, 2013) |
| "Practice guidelines recommend the use of low dose haloperidol when medication is needed to treat delirium with acute agitation in hospitalized older people." | 3.79 | Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. ( Dorokhine, I; Knapp, CM; Musuku, M; Patel, N; Zirker, W, 2013) |
| "This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital." | 3.79 | Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. ( Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013) |
| " Haloperidol, a butyrophenone derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care." | 3.79 | Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. ( Agar M, M; Crawford, GB; Currow, DC; Doogue, M; Litster, C; Michael, N; Phillips, J; Quinn, SJ; Rowett, D, 2013) |
| "Two female Caucasian acute promyelocytic leukemia patients aged 46 and 56 years developed delirium during their induction treatment with all-trans retinoic acid and idarubicin." | 3.79 | Delirium in acute promyelocytic leukemia patients: two case reports. ( Ambrosio, M; Cavallari, M; Cibien, F; Cuneo, A; Daghia, G; Formigaro, L; Lista, E; Martinelli, S; Pizzolato, M; Rigolin, GM; Sofritti, O, 2013) |
| "this is a secondary analysis based on data from a controlled clinical trial evaluating efficacy of haloperidol prophylaxis for delirium conducted in a large medical school-affiliated general hospital in Alkmaar, The Netherlands." | 3.77 | Mortality associated with delirium after hip-surgery: a 2-year follow-up study. ( de Jonghe, JF; Eikelenboom, P; Kalisvaart, KJ; Kat, MG; van der Ploeg, T; van Gool, WA; Vreeswijk, R, 2011) |
| "To compare the efficacy and tolerability of aripiprazole and haloperidol in the amelioration of distressing symptoms of delirium and its motoric subtypes." | 3.77 | Aripiprazole and haloperidol in the treatment of delirium. ( Boettger, S; Breitbart, W; Friedlander, M; Passik, S, 2011) |
| "Secondary analysis of haloperidol prophylaxis for delirium clinical trial data." | 3.77 | Anesthesia and postoperative delirium in older adults undergoing hip surgery. ( de Jonghe, JF; Eikelenboom, P; Groot, E; Kalisvaart, KJ; Ploeg, TV; Schmand, B; Slor, CJ; Snoeck, M; van Gool, WA; Vreeswijk, R, 2011) |
| "Age, use of opioids, and haloperidol were associated with persistent delirium." | 3.76 | Factors associated with persistent delirium after intensive care unit admission in an older medical patient population. ( Araujo, KL; Murphy, TE; Pisani, MA; Van Ness, PH, 2010) |
| " We measured CAM-ICU compliance, interrater reliability, and delirium knowledge, and compared the haloperidol use, as a proxy for delirium incidence, before and after the implementation of the CAM-ICU." | 3.75 | Implementation of a delirium assessment tool in the ICU can influence haloperidol use. ( Pickkers, P; Roodbol, G; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, H, 2009) |
| "The aim of this study was to determine the risk of adverse events for risperidone and haloperidol in delirium patients." | 3.74 | Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. ( Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K, 2007) |
| "We explored the possibility that the administration of intravenous dopamine increases the risk for delirium as manifested by need for haloperidol." | 3.71 | Is dopamine administration possibly a risk factor for delirium? ( Kraemer, HC; Sommer, BR; Wise, LC, 2002) |
| " Administration of large intravenous doses of haloperidol was necessary for control of psychomotor agitation due to delirium." | 3.70 | Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. ( Bélisle, S; Carrier, M; Cartier, R; Denault, AY; Perrault, LP, 2000) |
| "A 52-year-old woman with bipolar disorder, rapid-cycling type, developed delirium while taking therapeutic doses of carbamazepine and neuroleptics." | 3.67 | Case report of a possible interaction between neuroleptics and carbamazepine. ( Ciccone, JR; Kanter, GL; Yerevanian, BI, 1984) |
| "More than 2,000 medically ill patients with delirium have been treated by intravenous administration of a combination of haloperidol and lorazepam." | 3.67 | Emergency intravenous sedation of the delirious, medically ill patient. ( Adams, F, 1988) |
| "A case of agitated delirium secondary to bilateral occipital cerebral infarctions in a cancer patient was refractory to trials of large doses of intravenous psychotropic agents, but continuous intravenous infusion of haloperidol controlled agitation rapidly and safely." | 3.67 | Treatment of severe, refractory agitation with a haloperidol drip. ( Adams, F; Fernandez, F; Holmes, VF; Kavanaugh, JJ, 1988) |
| "A report is made on two cases of a pharmacogenic delirium as a result of combined lithium-haloperidol therapy, and on one case of lithium-induced diabetes insipidus renales with second-degree high pressure." | 3.65 | [Dangerous side effects of lithium therapy]. ( Ehle, G; Uebelhack, R, 1977) |
| "The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life." | 3.11 | An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. ( Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ, 2022) |
| "Delirium is a common disorder among hospitalized older patients and results in increased morbidity and mortality." | 3.01 | Efficacy of quetiapine for delirium prevention in hospitalized older medical patients: a randomized double-blind controlled trial. ( Assavapokee, T; Chansirikarnjana, S; Charernwat, P; Ittasakul, P; Ngamkala, T; Ruangritchankul, S; Saranburut, K; Sriwannopas, O; Sukumalin, L; Thanapluetiwong, S, 2021) |
| " Treatment with antipsychotics in this limited pilot trial did not improve the number of days alive without delirium or coma, nor did it increase adverse outcomes." | 2.75 | Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. ( Bernard, GR; Canonico, AE; Carson, SS; Dittus, RS; Ely, EW; Girard, TD; Meltzer, HY; Pandharipande, PP; Pun, BT; Schmidt, GA; Shintani, AK; Thompson, JL; Wright, PE, 2010) |
| "Delirium is a syndrome characterised by an acute disturbance of attention and awareness which develops over a short time period and fluctuates in severity over the course of the day." | 2.66 | Drug therapy for delirium in terminally ill adults. ( Candy, B; Finucane, AM; Jones, L; Leurent, B; Sampson, EL; Stone, P; Tookman, A, 2020) |
| " Dosing recommendations however are often based on strategies used in patients with normal body habitus." | 2.66 | Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. ( Barletta, JF; Erstad, BL, 2020) |
| "Since pharmacological treatment of delirium is not highly effective, focus of research has shifted towards developing preventive strategies." | 2.66 | Antipsychotic Drugs in Prevention of Postoperative Delirium-What Is Known in 2020? ( Czempik, PF; Dziech, M; Krzych, ŁJ; Pluta, MP; Szczepańska, AJ, 2020) |
| "Patients with delirium are frequently treated with antipsychotic medications that are well known to induce akathisia as a side effect." | 2.53 | Antipsychotic-induced akathisia in delirium: A systematic review. ( Alici, Y; Forcen, FE; Matsoukas, K, 2016) |
| "The therapy of delirium is mostly determined by non-pharmacological measures aiming at early identification, reorientation and mobilization of the patient, improving cerebral activity and establishing adequate wake-sleep cycles." | 2.53 | [Delirium and delirium management in critically ill patients]. ( Kersten, A; Reith, S, 2016) |
| "Delirium is the most common and distressing neuropsychiatric syndrome in cancer patients." | 2.53 | Neuroleptics in the management of delirium in patients with advanced cancer. ( Bruera, E; Dev, R; Hui, D, 2016) |
| "Delirium is a complex but common disorder in palliative care with a prevalence between 13 and 88 % but a particular frequency at the end of life (terminal delirium)." | 2.52 | Management of delirium in palliative care: a review. ( Berardi, MA; Caraceni, A; Caruso, R; Grassi, L; Mitchell, AJ; Nanni, MG; Riba, M, 2015) |
| " Dosing schedules are derived from expert opinion and various clinical practice guidelines as evidence-based data from palliative care settings are limited." | 2.50 | Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. ( Breitbart, W; Bruera, E; Bush, SH; Currow, DC; Davis, DHJ; Gagnon, B; Gagnon, PR; Hartwick, M; Kanji, S; Lawlor, PG; Meagher, D; Pereira, JL; Rabheru, K; Regnier, L; Wright, D, 2014) |
| "Treatment with lorazepam only should be avoided." | 2.49 | [Pharmacological treatment of delirium in palliative care patients. A systematic literature review]. ( Golla, H; Perrar, KM; Voltz, R, 2013) |
| "Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia." | 2.48 | Role of haloperidol in palliative medicine: an update. ( Prommer, E, 2012) |
| "Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects." | 2.48 | Haloperidol dosing strategies in the treatment of delirium in the critically ill. ( Ensom, MH; Loh, GW; Mabasa, VH; Wang, EH, 2012) |
| "Delirium is frequently encountered in the ICU and is associated with significant adverse outcomes." | 2.48 | ICU delirium: an update. ( Jones, SF; Pisani, MA, 2012) |
| "Delirium is one of the most serious and common complications that up to one third of older patients admitted to hospital develop." | 2.48 | Confusion, agitation and delirium. ( Martin, JJ, 2012) |
| "The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction." | 2.48 | Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012) |
| "Delirium is a syndrome characterised by a disturbance of consciousness (often fluctuating), cognition and perception." | 2.48 | Drug therapy for delirium in terminally ill adult patients. ( Candy, B; Jackson, KC; Jones, L; King, M; Leurent, B; Tookman, A, 2012) |
| "The primary goal in the detection and treatment of ICU delirium is to ensure the safety of the patient and caregiver(s)." | 2.46 | Intensive care unit delirium. ( Bruno, JJ; Warren, ML, 2010) |
| "Delirium is common in the last weeks of life, occurring in 26% to 44% of people with advanced cancer in hospital, and in up to 88% of people with terminal illness in the last days of life." | 2.45 | Delirium at the end of life. ( Keeley, PW, 2009) |
| "Delirium is a common problem in older patients admitted to the hospital." | 2.44 | [Delirium--management in the hospital: diagnosis and treatment]. ( Rahn, A, 2008) |
| "Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated." | 2.44 | Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. ( Battistone, S; Devlin, JW; Fong, JJ; Rea, RS, 2007) |
| "Oral haloperidol was associated with more frequent extrapyramidal side effects, but overall, all agents were well tolerated." | 2.43 | Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. ( Lacasse, H; Perreault, MM; Williamson, DR, 2006) |
| "Delirium affects 10 to 30 percent of hospitalized patients with medical illness; more than 50 percent of persons in certain high-risk populations are affected." | 2.42 | Delirium. ( Gleason, OC, 2003) |
| "Delirium is highly prevalent in terminally ill patients, especially in the last weeks of life, when some cognitive impairment develops in as many as 85% of patients." | 2.41 | Delirium in the terminally ill. ( Breitbart, W; Strout, D, 2000) |
| "Delirium is frequently underdiagnosed in clinical practice." | 2.41 | Diagnosing and managing delirium in the elderly. ( Conn, DK; Lieff, S, 2001) |
| " Cramping abdominal pain associated with mechanical bowel obstruction often can be managed with morphine (titrating the dosage for pain) and octreotide." | 2.41 | Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea. ( Alexander, CS; Ross, DD, 2001) |
| "Delirium is a common psychiatric complication in somatically ill in-patients and is associated with increased morbidity and mortality, longer lengths of stay and higher cost of treatment." | 2.41 | [Diagnosis and treatment of delirium]. ( Hepp, U, 2002) |
| "The occurrence of confusion in the elderly patient should alert the physician to the need of investigation to detect underlying severe disease without delay." | 2.39 | [Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis]. ( Pitkälä, K, 1996) |
| "Pharmacologic treatments of delirium in adults and children are outlined, with particular emphasis on intravenous use of butyrophenone neuroleptics." | 2.39 | Delirium. Advances in diagnosis, pathophysiology, and treatment. ( Trzepacz, PT, 1996) |
| "Delirium is the second most common psychiatric diagnosis among hospitalized elderly cancer patients." | 2.38 | Delirium in cancer patients. ( Holland, J; Stiefel, F, 1991) |
| "Two patients who developed choreoathetosis in the course of lithium treatment are described, and other cases of choreoathetosis in lithium-treated patients are reviewed." | 2.38 | Choreoathetosis: a sign of lithium toxicity. ( Reed, SM; Timmerman, I; Wise, MG, 1989) |
| "Delirium is the most common neuropsychiatric complication of hospitalized AIDS patients." | 2.38 | Management of delirium in terminally ill AIDS patients. ( Fernandez, F; Levy, JK; Mansell, PW, 1989) |
| "Delirium is an acute disturbance in attention, cognition, and awareness that fluctuates over time." | 1.91 | Delirium in Older Persons: Prevention, Evaluation, and Management. ( Chin, E; Jaqua, EE; Nguyen, VTN, 2023) |
| "Delirium is highly prevalent in the intensive care unit (ICU) and is associated with high morbidity and mortality." | 1.72 | Agents intervening against delirium in the intensive care unit trial-Protocol for a secondary Bayesian analysis. ( Andersen-Ranberg, N; Andreasen, AS; Bestle, MH; Citerio, G; Damgaard, K; Dey, N; Granholm, A; Hästbacka, J; Jensen, TB; Mathiesen, O; Morgan, MPG; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Sommer, T; Uslu, B; Weber, SO, 2022) |
| "The most prescribed treatment for delirium was injectable haloperidol (n=82 490; 56." | 1.72 | Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database. ( Igarashi, M; Ogawa, A; Okuda, S; Okumura, Y; Okuyama, K; P Qureshi, Z; Sano, H; Takahashi, K; Tokita, S; Ueda, N, 2022) |
| "Risperidone has weight-based dosing and a liquid dosage form available, making it a good option for use in the NICU." | 1.62 | Delirium in the NICU: Risk or Reality? ( Liviskie, C; McPherson, C, 2021) |
| "As its name suggests, delirious mania presents as a mixture of hyperactive delirium and mania; additional features may include psychosis, autonomic activation, and catatonia." | 1.62 | Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium. ( Ainsworth, A; Andrews, P; Ely, EW; Oldham, MA; Roy, K; Wilson, JE, 2021) |
| "Postoperative delirium is the most common neurological complication of cardiac surgery." | 1.48 | The influence of oxygen delivery during cardiopulmonary bypass on the incidence of delirium in CABG patients; a retrospective study. ( Golab, H; Leenders, J; Overdevest, E; van Straten, B, 2018) |
| " We therefore designed a population pharmacokinetic study to gain more insight into the pharmacokinetics of haloperidol in terminally ill patients and to find clinically relevant covariates that may be used in developing an individualised dosing regimen." | 1.46 | Population pharmacokinetics of haloperidol in terminally ill adult patients. ( Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017) |
| "Strategies to prevent and treat delirium during hospitalization for hip fracture have been less studied." | 1.40 | [Delirium prevention and treatment in elderly hip fracture]. ( Formiga, F; Robles, MJ; Vidán, MT, 2014) |
| "Agitated delirium is a palliative care emergency." | 1.40 | High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. ( Bascom, PB; Bordley, JL; Lawton, AJ, 2014) |
| "Haloperidol was initiated at 5 mg intravenous every 6 h and titrated up to a dose of 60 mg /day over 5 days." | 1.39 | Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? ( Adelman, M; Dixit, D; Shrestha, P, 2013) |
| "To determine the dosing patterns and total doses of fentanyl, lorazepam, and haloperidol according to nursing shift in a cohort of older patients in a medical intensive care unit." | 1.39 | Patterns of opiate, benzodiazepine, and antipsychotic drug dosing in older patients in a medical intensive care unit. ( Akgün, KM; Araujo, KL; Bramley, K; Murphy, TE; Pisani, MA; Vest, MT, 2013) |
| "However, interictal delirium is uncommon in absence of risk factors." | 1.38 | Delayed onset and prolonged interictal delirium following electroconvulsive therapy. ( Praharaj, SK; Selvaraj, AG, 2012) |
| "Haloperidol was perceived by many (42%) to have 1 or more randomized trials supporting its use for delirium and Food and Drug Administration approval for this indication (34%)." | 1.37 | Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. ( Bhat, S; Devlin, JW; Roberts, RJ; Skrobik, Y, 2011) |
| "Delirium is an acute organ dysfunction common amongst patients treated in intensive care units." | 1.36 | A national survey of the management of delirium in UK intensive care units. ( Barber, V; Ely, EW; Mac Sweeney, R; McAuley, DF; Page, V; Perkins, GD; Young, JD, 2010) |
| " Limited information is available regarding the dosage requirements and efficacy of neuroleptics in the palliative care setting." | 1.36 | Neuroleptic dose in the management of delirium in patients with advanced cancer. ( Bruera, E; Bush, SH; Gallo, LE; Hui, D; Palmer, JL; Yennurajalingam, S, 2010) |
| "Delirium is a common, underdiagnosed and serious problem in intensive care unit patients." | 1.35 | Tackling agitated delirium--the tip of the iceberg. ( Page, VJ, 2009) |
| "Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people." | 1.34 | Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. ( Cotroneo, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Lacava, R, 2007) |
| "Haloperidol was associated with significantly lower hospital mortality." | 1.33 | Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. ( Angus, DC; Clermont, G; Fink, MP; Kersten, A; Kong, L; Milbrandt, EB; Weissfeld, LA, 2005) |
| "Delirium is a syndrome, not a disease, and has many causes, all of which result in a similar pattern of signs and symptoms relating to a patient's level of consciousness and cognitive impairment." | 1.33 | Case report: delirium associated with ovarian hyperstimulation syndrome. ( Karamustafalioglu, O; Mercan, R; Mercan, S, 2005) |
| "The authors use a clinical case of a paranoiac patient to highlight the role played by writing, drawing, and painting in the psychoanalytical treatment of psychosis." | 1.33 | Reading and writing: psychoanalytical treatment in a case of paranoia. ( Assadi, TC; Bueno, DS; Colucci, VL; de Cerqueira Leite, AC; Freire, JM; Pereira, ME; Portella, LB; Ribes, SI, 2005) |
| "Therefore treatment of delirium with a cholinesterase-inhibitor seems logical." | 1.32 | [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]. ( Boelaarts, L; de Jonghe, JF; Hovinga, IM; Kalisvaart, CJ; Kat, MG, 2004) |
| "A new delirium was induced when, after discharge from the hospital, betahistine was restarted because of dizziness." | 1.32 | [Delirium in a 73-year-old man after many years of unwise use of betahistine]. ( Hoenders, HJ; Wilterdink, J, 2004) |
| "Depression in cancer patients is common and occurs throughout the course of cancer illness." | 1.31 | [Management of psychiatric symptoms in cancer patients]. ( Uchitomi, Y, 2002) |
| "Haloperidol was used in 67% cases for the treatment of delirium." | 1.31 | A survey on the drug therapy for delirium. ( Endo, T; Hara, T; Someya, T; Suzuki, J; Yagi, G, 2001) |
| "The delirium was reversible when all drugs were stopped; however, dyskinesia was found to be persistent after a period of 6 months." | 1.30 | Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. ( Berger, M; Brandt, C; Normann, C; Walden, J, 1998) |
| "Delirium in the cancer patient is particularly problematic given the coexisting medical problems these patients experience." | 1.29 | A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. ( Baile, WF; Meyers, CA; Olofsson, SM; Valentine, AD; Weitzner, MA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (8.84) | 18.7374 |
| 1990's | 30 (9.15) | 18.2507 |
| 2000's | 63 (19.21) | 29.6817 |
| 2010's | 153 (46.65) | 24.3611 |
| 2020's | 53 (16.16) | 2.80 |
| Authors | Studies |
|---|---|
| Tillemans, MPH | 1 |
| Butterhoff-Terlingen, MH | 1 |
| Stuffken, R | 1 |
| Vreeswijk, R | 6 |
| Egberts, TCG | 1 |
| Kalisvaart, KJ | 6 |
| Liu, J | 1 |
| Yu, D | 1 |
| Li, J | 1 |
| Sato, J | 1 |
| Tanaka, R | 1 |
| Yoshihiro, S | 1 |
| Taito, S | 1 |
| Lyu, XJ | 1 |
| Kan, AD | 1 |
| Chong, PH | 1 |
| Lin, K | 1 |
| Koh, YH | 1 |
| Yeo, ZZ | 1 |
| Andersen-Ranberg, N | 2 |
| Poulsen, LM | 5 |
| Perner, A | 8 |
| Hästbacka, J | 6 |
| Morgan, MPG | 3 |
| Citerio, G | 6 |
| Oxenbøll-Collet, M | 3 |
| Weber, SO | 5 |
| Andreasen, AS | 4 |
| Bestle, MH | 3 |
| Uslu, B | 4 |
| Pedersen, HBS | 3 |
| Nielsen, LG | 4 |
| Damgaard, K | 2 |
| Jensen, TB | 4 |
| Sommer, T | 2 |
| Dey, N | 4 |
| Mathiesen, O | 7 |
| Granholm, A | 2 |
| Matsuda, Y | 2 |
| Morita, T | 1 |
| Oya, K | 1 |
| Tagami, K | 1 |
| Naito, AS | 1 |
| Kashiwagi, H | 1 |
| Otani, H | 1 |
| Ueda, N | 1 |
| Igarashi, M | 1 |
| Okuyama, K | 1 |
| Sano, H | 1 |
| Takahashi, K | 1 |
| P Qureshi, Z | 1 |
| Tokita, S | 1 |
| Ogawa, A | 1 |
| Okumura, Y | 1 |
| Okuda, S | 1 |
| Reisinger, M | 1 |
| Reininghaus, EZ | 1 |
| Biasi, J | 1 |
| Fellendorf, FT | 1 |
| Schoberer, D | 1 |
| Jaworska, N | 1 |
| Moss, SJ | 1 |
| Krewulak, KD | 1 |
| Stelfox, Z | 1 |
| Niven, DJ | 1 |
| Ismail, Z | 1 |
| Burry, LD | 1 |
| Fiest, KM | 1 |
| Andersen-Ranberg, NC | 4 |
| Wetterslev, J | 6 |
| Estrup, S | 3 |
| Morgan, M | 2 |
| Caballero, J | 4 |
| Lange, T | 4 |
| Kjær, MN | 1 |
| Ebdrup, BH | 3 |
| Engstrøm, J | 1 |
| Olsen, MH | 1 |
| Oxenbøll Collet, M | 1 |
| Mortensen, CB | 2 |
| Scharling Pedersen, H | 1 |
| Gramstrup Nielsen, L | 1 |
| Toft Boesen, HC | 1 |
| Jensen, JV | 1 |
| Nebrich, L | 1 |
| La Cour, K | 1 |
| Laigaard, J | 1 |
| Haurum, C | 1 |
| Olesen, MW | 1 |
| Overgaard-Steensen, C | 1 |
| Westergaard, B | 1 |
| Brand, B | 1 |
| Kingo Vesterlund, G | 1 |
| Thornberg Kyhnauv, P | 1 |
| Mikkelsen, VS | 1 |
| Hyttel-Sørensen, S | 1 |
| de Haas, I | 1 |
| Aagaard, SR | 1 |
| Nielsen, LO | 1 |
| Eriksen, AS | 1 |
| Rasmussen, BS | 1 |
| Brix, H | 1 |
| Hildebrandt, T | 2 |
| Schønemann-Lund, M | 1 |
| Fjeldsøe-Nielsen, H | 1 |
| Kuivalainen, AM | 1 |
| Marcantonio, ER | 2 |
| Hayase, T | 1 |
| Saiga, H | 1 |
| Yamaguchi, T | 1 |
| Ando, K | 1 |
| Suzuki, A | 1 |
| Yoshida, H | 1 |
| Zhang, Y | 1 |
| Wilkins, JM | 1 |
| Bessette, LG | 1 |
| York, C | 1 |
| Wong, V | 1 |
| Lin, KJ | 1 |
| Tanner, M | 1 |
| Collet, MO | 4 |
| Bestle, M | 2 |
| Pedersen, HS | 1 |
| Charlier, C | 1 |
| Jaren, L | 1 |
| Aebischer, O | 1 |
| Minami, T | 1 |
| Watanabe, H | 1 |
| Kato, T | 1 |
| Ikeda, K | 1 |
| Ueno, K | 1 |
| Matsuyama, A | 1 |
| Maeda, J | 1 |
| Sakai, Y | 2 |
| Harada, H | 1 |
| Kuriyama, A | 1 |
| Yamaji, K | 1 |
| Kitajima, N | 1 |
| Kamei, J | 1 |
| Takatani, Y | 1 |
| Sato, Y | 1 |
| Yamashita, Y | 1 |
| Mizota, T | 1 |
| Ohtsuru, S | 1 |
| Huang, YQ | 1 |
| Weiss, S | 1 |
| Gros, P | 1 |
| Wong, E | 1 |
| Piché, PP | 1 |
| Vyas, MV | 1 |
| Tam, AKH | 1 |
| Watt, JA | 1 |
| Jaqua, EE | 1 |
| Nguyen, VTN | 1 |
| Chin, E | 1 |
| Smit, L | 3 |
| Slooter, AJC | 6 |
| Devlin, JW | 11 |
| Trogrlic, Z | 3 |
| Hunfeld, NGM | 3 |
| Osse, RJ | 3 |
| Ponssen, HH | 2 |
| Brouwers, AJBW | 1 |
| Schoonderbeek, JF | 1 |
| Simons, KS | 3 |
| van den Boogaard, M | 11 |
| Lens, JA | 1 |
| Boer, DP | 1 |
| Gommers, DAMPJ | 1 |
| Rietdijk, WJR | 2 |
| van der Jagt, M | 5 |
| Dietrich, M | 1 |
| Reuß, CJ | 1 |
| Beynon, C | 1 |
| Hecker, A | 1 |
| Jungk, C | 1 |
| Michalski, D | 1 |
| Nusshag, C | 1 |
| Schmidt, K | 1 |
| Weigand, MA | 1 |
| Bernhard, M | 1 |
| Brenner, T | 1 |
| Nikooie, R | 2 |
| Neufeld, KJ | 3 |
| Oh, ES | 2 |
| Wilson, LM | 2 |
| Zhang, A | 2 |
| Robinson, KA | 2 |
| Needham, DM | 2 |
| Lewis, KA | 1 |
| Spence, J | 1 |
| Dionne, JC | 1 |
| Rochwerg, B | 1 |
| Barbateskovic, M | 3 |
| Krauss, SR | 1 |
| Jakobsen, JC | 2 |
| Chen, Z | 1 |
| Chen, R | 1 |
| Zheng, D | 1 |
| Su, Y | 1 |
| Wen, S | 1 |
| Guo, H | 1 |
| Ye, Z | 1 |
| Deng, Y | 1 |
| Liu, G | 1 |
| Zuo, L | 1 |
| Wei, X | 1 |
| Hou, Y | 1 |
| Finucane, AM | 1 |
| Jones, L | 2 |
| Leurent, B | 2 |
| Sampson, EL | 1 |
| Stone, P | 1 |
| Tookman, A | 2 |
| Candy, B | 2 |
| Li, Y | 1 |
| Ma, J | 1 |
| Jin, Y | 1 |
| Li, N | 1 |
| Zheng, R | 1 |
| Mu, W | 1 |
| Wang, J | 2 |
| Si, JH | 1 |
| Chen, J | 1 |
| Shang, HC | 1 |
| van der Vorst, MJDL | 1 |
| Neefjes, ECW | 1 |
| Boddaert, MSA | 1 |
| Verdegaal, BATT | 1 |
| Beeker, A | 1 |
| Teunissen, SCC | 1 |
| Beekman, ATF | 1 |
| Wilschut, JA | 1 |
| Berkhof, J | 1 |
| Zuurmond, WWA | 1 |
| Verheul, HMW | 1 |
| Nieboer, D | 1 |
| Koch, BCP | 2 |
| van Schaik, RHN | 1 |
| Kim, MS | 1 |
| Rhim, HC | 1 |
| Park, A | 1 |
| Kim, H | 1 |
| Han, KM | 1 |
| Patkar, AA | 2 |
| Pae, CU | 1 |
| Han, C | 2 |
| Hui, D | 9 |
| De La Rosa, A | 2 |
| Wilson, A | 2 |
| Nguyen, T | 3 |
| Wu, J | 1 |
| Delgado-Guay, M | 2 |
| Azhar, A | 1 |
| Arthur, J | 2 |
| Epner, D | 2 |
| Haider, A | 1 |
| De La Cruz, M | 2 |
| Heung, Y | 1 |
| Tanco, K | 2 |
| Dalal, S | 2 |
| Reddy, A | 3 |
| Williams, J | 2 |
| Amin, S | 2 |
| Armstrong, TS | 1 |
| Breitbart, W | 7 |
| Bruera, E | 10 |
| Erstad, BL | 1 |
| Barletta, JF | 1 |
| Sofie Andreasen, A | 1 |
| Thee, C | 2 |
| Remelli, F | 1 |
| Bugada, M | 1 |
| Matteucci, G | 1 |
| Brunori, M | 1 |
| Gianotti, G | 1 |
| Zurlo, A | 1 |
| Volpato, S | 1 |
| Pluta, MP | 1 |
| Dziech, M | 1 |
| Czempik, PF | 1 |
| Szczepańska, AJ | 1 |
| Krzych, ŁJ | 1 |
| Khoodoruth, MAS | 1 |
| Khan, AA | 1 |
| Gommers, D | 1 |
| Hollinger, A | 2 |
| Rüst, CA | 1 |
| Riegger, H | 2 |
| Gysi, B | 1 |
| Tran, F | 1 |
| Brügger, J | 1 |
| Huber, J | 1 |
| Toft, K | 2 |
| Surbeck, M | 1 |
| Schmid, HR | 1 |
| Rentsch, K | 1 |
| Steiner, L | 1 |
| Siegemund, M | 2 |
| Lodewijckx, E | 1 |
| Debain, A | 1 |
| Lieten, S | 1 |
| Bravenboer, B | 1 |
| Mets, T | 1 |
| Dijkstra-Kersten, SMA | 1 |
| Zaal, IJ | 1 |
| Marra, A | 1 |
| Vargas, M | 1 |
| Buonanno, P | 1 |
| Iacovazzo, C | 1 |
| Kotfis, K | 1 |
| Servillo, G | 1 |
| Cronin, MT | 1 |
| Di Gennaro, JL | 1 |
| Watson, RS | 1 |
| Dervan, LA | 1 |
| Liviskie, C | 1 |
| McPherson, C | 1 |
| Thanapluetiwong, S | 1 |
| Ruangritchankul, S | 1 |
| Sriwannopas, O | 1 |
| Chansirikarnjana, S | 1 |
| Ittasakul, P | 1 |
| Ngamkala, T | 1 |
| Sukumalin, L | 1 |
| Charernwat, P | 1 |
| Saranburut, K | 1 |
| Assavapokee, T | 1 |
| Duprey, MS | 2 |
| van der Hoeven, JG | 5 |
| Pickkers, P | 9 |
| Briesacher, BA | 1 |
| Saczynski, JS | 1 |
| Griffith, JL | 1 |
| Santos, CD | 1 |
| Rose, MQ | 1 |
| Park, SK | 1 |
| Lim, T | 1 |
| Cho, H | 1 |
| Yoon, HK | 1 |
| Lee, HJ | 2 |
| Lee, JH | 1 |
| Yoo, S | 1 |
| Kim, JT | 1 |
| Kim, WH | 1 |
| Pinkhasov, AM | 1 |
| Collantes, CMC | 1 |
| Chen, M | 2 |
| Fazzari, MJ | 1 |
| Coriolan, S | 1 |
| Lam, S | 1 |
| Tang, M | 1 |
| Prendergast, NT | 1 |
| Girard, TD | 5 |
| Wilson, JE | 1 |
| Andrews, P | 1 |
| Ainsworth, A | 1 |
| Roy, K | 1 |
| Ely, EW | 7 |
| Oldham, MA | 2 |
| Urbauer, DL | 1 |
| Lee, J | 1 |
| Holbrook, A | 1 |
| Hirst, JM | 1 |
| Vaughan, CL | 1 |
| Irwin, SA | 1 |
| Peng, ZY | 1 |
| Zhou, WH | 1 |
| Hu, B | 1 |
| Rao, X | 1 |
| Li, JG | 1 |
| Santos, E | 2 |
| Cardoso, D | 2 |
| Neves, H | 2 |
| Cunha, M | 2 |
| Rodrigues, M | 2 |
| Apóstolo, J | 2 |
| Valentine, A | 1 |
| Bogman, ACCF | 1 |
| Schieveld, JNM | 2 |
| Elsayem, AF | 1 |
| Fisch, MJ | 1 |
| Morgan, AA | 1 |
| Sinclair, CT | 1 |
| Agar, MR | 3 |
| Draper, B | 2 |
| Caplan, GA | 2 |
| Franken, LG | 1 |
| Mathot, RAA | 1 |
| Masman, AD | 1 |
| Baar, FPM | 1 |
| Tibboel, D | 3 |
| van Gelder, T | 1 |
| de Winter, BCM | 1 |
| Regan, DW | 1 |
| Kashiwagi, D | 1 |
| Dougan, B | 1 |
| Sundsted, K | 1 |
| Mauck, K | 1 |
| Boettger, S | 3 |
| Knöpfel, S | 1 |
| Schubert, M | 1 |
| Garcia Nuñez, D | 1 |
| Plichta, MM | 1 |
| Klaghofer, R | 1 |
| Jenewein, J | 2 |
| Thom, RP | 1 |
| Mock, CK | 1 |
| Teslyar, P | 1 |
| Masiran, R | 1 |
| Abdul Aziz, MF | 1 |
| Frisbee-Hume, S | 1 |
| Dibaj, SS | 2 |
| Walker, P | 1 |
| Zhukovsky, DS | 1 |
| Vidal, M | 1 |
| Hall, S | 1 |
| Liu, D | 1 |
| Hess, K | 2 |
| Schrijver, EJM | 2 |
| de Vries, OJ | 3 |
| van de Ven, PM | 2 |
| Bet, PM | 2 |
| Kamper, AM | 2 |
| Diepeveen, SHA | 1 |
| van Marum, RJ | 4 |
| van Strien, AM | 4 |
| Anten, S | 2 |
| Lagaay, AM | 2 |
| Boelaarts, L | 3 |
| Bloemers, FW | 1 |
| Kramer, MHH | 1 |
| Nanayakkara, PWB | 2 |
| Kathirvel, N | 1 |
| Ghosh, AK | 1 |
| Teale, EA | 1 |
| van Keulen, K | 1 |
| Knol, W | 1 |
| Jung, DM | 1 |
| Ahn, HJ | 1 |
| Yang, M | 1 |
| Kim, JA | 1 |
| Kim, DK | 1 |
| Lee, SM | 1 |
| Park, JH | 1 |
| Slooff, VD | 2 |
| van den Dungen, DK | 1 |
| van Beusekom, BS | 2 |
| Jessurun, N | 2 |
| Ista, E | 1 |
| de Wildt, SN | 2 |
| Kraus, SR | 1 |
| Brüggemann, RJM | 1 |
| Schoonhoven, L | 4 |
| Beishuizen, A | 3 |
| Vermeijden, JW | 1 |
| Pretorius, D | 1 |
| de Koning, J | 1 |
| Dennesen, PJW | 1 |
| Van der Voort, PHJ | 3 |
| Houterman, S | 2 |
| Besselink, A | 1 |
| Hofstra, LS | 1 |
| Spronk, PE | 4 |
| van den Bergh, W | 1 |
| Donker, DW | 1 |
| Fuchs, M | 1 |
| Karakus, A | 2 |
| Koeman, M | 1 |
| van Duijnhoven, M | 1 |
| Hannink, G | 1 |
| Dev, R | 2 |
| Reddy, S | 1 |
| Seifert, B | 1 |
| Blum, A | 1 |
| Zehnder, T | 1 |
| Shen, YZ | 1 |
| Peng, K | 1 |
| Zhang, J | 1 |
| Meng, XW | 1 |
| Ji, FH | 1 |
| Schildmann, E | 1 |
| Pörnbacher, S | 1 |
| Kalies, H | 1 |
| Bausewein, C | 1 |
| Shrikant Kulkarni, N | 1 |
| Sonneville, R | 1 |
| Bozza, FA | 2 |
| Nydahl, P | 1 |
| Schandl, A | 1 |
| Wøien, H | 1 |
| Haenggi, M | 1 |
| Colpaert, K | 1 |
| Rose, L | 2 |
| Jensen, A | 1 |
| Krog, MB | 1 |
| Egerod, I | 2 |
| Nibro, HL | 1 |
| Burry, L | 1 |
| Mehta, S | 1 |
| Perreault, MM | 2 |
| Luxenberg, JS | 1 |
| Siddiqi, N | 1 |
| Hutton, B | 1 |
| Fergusson, DA | 1 |
| Bell, C | 1 |
| Latronico, N | 1 |
| Leenders, J | 1 |
| Overdevest, E | 1 |
| van Straten, B | 1 |
| Golab, H | 1 |
| Strik, JJMH | 1 |
| Torbic, H | 1 |
| Duggal, A | 1 |
| van Schijndel, AW | 1 |
| Franssen, EJF | 1 |
| Rijkenberg, S | 1 |
| Garetto, F | 1 |
| Cancelli, F | 1 |
| Rossi, R | 1 |
| Maltoni, M | 1 |
| Bleck, TP | 1 |
| Exline, MC | 1 |
| Carson, SS | 2 |
| Hough, CL | 1 |
| Rock, P | 1 |
| Gong, MN | 1 |
| Douglas, IS | 1 |
| Malhotra, A | 1 |
| Owens, RL | 1 |
| Feinstein, DJ | 1 |
| Khan, B | 1 |
| Pisani, MA | 6 |
| Hyzy, RC | 1 |
| Schmidt, GA | 2 |
| Schweickert, WD | 1 |
| Hite, RD | 1 |
| Bowton, DL | 1 |
| Masica, AL | 1 |
| Thompson, JL | 2 |
| Chandrasekhar, R | 1 |
| Pun, BT | 2 |
| Strength, C | 1 |
| Boehm, LM | 1 |
| Jackson, JC | 1 |
| Pandharipande, PP | 2 |
| Brummel, NE | 1 |
| Hughes, CG | 1 |
| Patel, MB | 1 |
| Stollings, JL | 1 |
| Bernard, GR | 2 |
| Dittus, RS | 2 |
| Siuciuno, T | 1 |
| Shimakawa, N | 1 |
| Shibuya, H | 1 |
| Suzuki, H | 1 |
| Ozawa, A | 1 |
| Moriwaki, K | 1 |
| Hirao, M | 1 |
| Khan, BA | 3 |
| Perkins, AJ | 3 |
| Campbell, NL | 3 |
| Gao, S | 2 |
| Khan, SH | 2 |
| Wang, S | 2 |
| Fuchita, M | 1 |
| Weber, DJ | 1 |
| Zarzaur, BL | 2 |
| Boustani, MA | 4 |
| Kesler, K | 1 |
| Herling, SF | 1 |
| Greve, IE | 1 |
| Vasilevskis, EE | 1 |
| Bekker Mortensen, C | 1 |
| Møller, AM | 1 |
| Svenningsen, H | 1 |
| Thomsen, T | 1 |
| Zayed, Y | 1 |
| Barbarawi, M | 1 |
| Kheiri, B | 1 |
| Banifadel, M | 1 |
| Haykal, T | 1 |
| Chahine, A | 1 |
| Rashdan, L | 1 |
| Aburahma, A | 1 |
| Bachuwa, G | 1 |
| Seedahmed, E | 1 |
| Farber, MO | 1 |
| Ingravallo, F | 1 |
| de Nooijer, K | 1 |
| Pucci, V | 1 |
| Casini, C | 1 |
| Miccinesi, G | 1 |
| Rietjens, JAC | 1 |
| Morino, P | 1 |
| Wu, YC | 1 |
| Tseng, PT | 1 |
| Tu, YK | 1 |
| Hsu, CY | 1 |
| Liang, CS | 1 |
| Yeh, TC | 1 |
| Chen, TY | 1 |
| Chu, CS | 1 |
| Matsuoka, YJ | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Wada, S | 1 |
| Lin, PY | 1 |
| Chen, YW | 1 |
| Su, KP | 1 |
| Tenser, RB | 1 |
| Lee, HB | 1 |
| Ishiki, H | 1 |
| Satomi, E | 1 |
| Shimizu, K | 1 |
| Nishigaki, A | 1 |
| Kawano, T | 1 |
| Iwata, H | 1 |
| Aoyama, B | 1 |
| Yamanaka, D | 1 |
| Tateiwa, H | 1 |
| Shigematsu-Locatelli, M | 1 |
| Eguchi, S | 1 |
| Locatelli, FM | 1 |
| Yokoyama, M | 1 |
| Matsuoka, H | 1 |
| Agar, M | 1 |
| Vandersman, Z | 1 |
| Good, P | 1 |
| Fazekas, B | 2 |
| Brown, L | 1 |
| Hardy, J | 2 |
| Weil, J | 1 |
| Currow, DC | 5 |
| O'Regan, NA | 1 |
| Mohamad, MM | 1 |
| Meagher, DJ | 2 |
| Rood, PJT | 1 |
| Zegers, M | 1 |
| van der Woude, MCE | 1 |
| Zafrani, L | 1 |
| Perrar, KM | 1 |
| Golla, H | 1 |
| Voltz, R | 1 |
| Fongemie, JM | 1 |
| Al-Qadheeb, NS | 2 |
| Estes, NA | 1 |
| Roberts, RJ | 5 |
| Temtanakitpaisan, Y | 1 |
| Ruthazer, R | 2 |
| McLoughlin, L | 1 |
| Leonard, M | 1 |
| Hannon, N | 1 |
| Dunne, C | 1 |
| O'Regan, N | 1 |
| Zirker, W | 1 |
| Dorokhine, I | 1 |
| Knapp, CM | 1 |
| Patel, N | 1 |
| Musuku, M | 1 |
| Robles, MJ | 1 |
| Formiga, F | 1 |
| Vidán, MT | 1 |
| Atalan, N | 1 |
| Efe Sevim, M | 1 |
| Akgün, S | 1 |
| Fazlıoğulları, O | 1 |
| Başaran, C | 1 |
| Dixit, D | 1 |
| Shrestha, P | 1 |
| Adelman, M | 1 |
| Jones, C | 1 |
| Maneeton, B | 1 |
| Maneeton, N | 1 |
| Srisurapanont, M | 1 |
| Chittawatanarat, K | 1 |
| Bramley, K | 1 |
| Vest, MT | 1 |
| Akgün, KM | 1 |
| Araujo, KL | 4 |
| Murphy, TE | 4 |
| Yoon, HJ | 1 |
| Park, KM | 1 |
| Choi, WJ | 1 |
| Choi, SH | 1 |
| Park, JY | 1 |
| Kim, JJ | 1 |
| Seok, JH | 1 |
| Bascom, PB | 1 |
| Bordley, JL | 1 |
| Lawton, AJ | 1 |
| Crawford, GB | 2 |
| Agar M, M | 1 |
| Quinn, SJ | 2 |
| Phillips, J | 1 |
| Litster, C | 1 |
| Michael, N | 1 |
| Doogue, M | 1 |
| Rowett, D | 2 |
| Raudenska, M | 1 |
| Gumulec, J | 1 |
| Babula, P | 1 |
| Stracina, T | 1 |
| Sztalmachova, M | 1 |
| Polanska, H | 1 |
| Adam, V | 1 |
| Kizek, R | 1 |
| Novakova, M | 1 |
| Masarik, M | 1 |
| Rigolin, GM | 1 |
| Martinelli, S | 1 |
| Formigaro, L | 1 |
| Cibien, F | 1 |
| Lista, E | 1 |
| Cavallari, M | 1 |
| Ambrosio, M | 1 |
| Pizzolato, M | 1 |
| Daghia, G | 1 |
| Sofritti, O | 1 |
| Cuneo, A | 1 |
| Slooter, AJ | 2 |
| Brüggemann, RJ | 1 |
| Kuiper, MA | 2 |
| van der Voort, PH | 1 |
| Hoogendoorn, ME | 1 |
| Schouten, JA | 1 |
| Schrøder Pedersen, S | 1 |
| Kirkegaard, T | 1 |
| Balslev Jørgensen, M | 1 |
| Lind Jørgensen, V | 1 |
| Skrobik, Y | 7 |
| Page, VJ | 3 |
| Gates, S | 1 |
| Zhao, XB | 1 |
| Alce, T | 1 |
| Shintani, A | 1 |
| Jackson, J | 1 |
| Perkins, GD | 2 |
| McAuley, DF | 2 |
| Viana, MV | 1 |
| Moraes, RB | 1 |
| Tonietto, TA | 1 |
| Boniatti, MM | 1 |
| Bush, SH | 2 |
| Kanji, S | 1 |
| Pereira, JL | 1 |
| Davis, DHJ | 1 |
| Meagher, D | 1 |
| Rabheru, K | 1 |
| Wright, D | 1 |
| Hartwick, M | 1 |
| Gagnon, PR | 2 |
| Gagnon, B | 1 |
| Regnier, L | 1 |
| Lawlor, PG | 2 |
| Fukata, S | 2 |
| Kawabata, Y | 2 |
| Fujisiro, K | 1 |
| Katagawa, Y | 1 |
| Kuroiwa, K | 2 |
| Akiyama, H | 2 |
| Terabe, Y | 1 |
| Ando, M | 2 |
| Kawamura, T | 1 |
| Hattori, H | 2 |
| Mattison, ML | 1 |
| Catic, A | 1 |
| Davis, RB | 1 |
| Olveczky, D | 1 |
| Moran, J | 1 |
| Yang, J | 1 |
| Aronson, M | 1 |
| Zeidel, M | 1 |
| Lipsitz, L | 1 |
| Vermeulen Windsant-van den Tweel, A | 1 |
| Leliveld-van den Heuvel, M | 1 |
| di Biase, M | 1 |
| van den Brule, AJ | 1 |
| Schrijver, EJ | 2 |
| Verburg, A | 1 |
| de Graaf, K | 2 |
| Diepeveen, SH | 1 |
| Siegel, A | 1 |
| Kuipéri, E | 1 |
| Pons, D | 1 |
| Kramer, MH | 1 |
| Nanayakkara, PW | 2 |
| Spaans, E | 1 |
| van Puijenbroek, E | 1 |
| de Hoog, M | 1 |
| Tanimukai, H | 1 |
| Tsujimoto, H | 1 |
| Tokoro, A | 1 |
| Kanemura, S | 1 |
| Watanabe, M | 1 |
| Tsujio, I | 1 |
| Maeda, I | 1 |
| Takei, K | 1 |
| Nakajima, S | 1 |
| Taira, T | 1 |
| Tokuyama, M | 1 |
| Kai, T | 1 |
| Okamoto, Y | 1 |
| Goya, S | 1 |
| Kashiwagi, Y | 1 |
| Grassi, L | 1 |
| Caraceni, A | 1 |
| Mitchell, AJ | 1 |
| Nanni, MG | 1 |
| Berardi, MA | 1 |
| Caruso, R | 1 |
| Riba, M | 1 |
| Yara, M | 1 |
| Tomino, M | 1 |
| Miyata, K | 1 |
| Ishida, Y | 1 |
| Saiki, I | 1 |
| Seta, N | 1 |
| Hara, N | 1 |
| Uchino, H | 1 |
| Kiberd, M | 1 |
| Hall, R | 1 |
| Blom, MT | 1 |
| Jansen, S | 1 |
| de Jonghe, A | 1 |
| van Munster, BC | 1 |
| de Boer, A | 1 |
| de Rooij, SE | 1 |
| Tan, HL | 1 |
| van der Velde, N | 1 |
| Serafim, RB | 1 |
| Soares, M | 1 |
| do Brasil, PE | 1 |
| Tura, BR | 1 |
| Salluh, JI | 1 |
| Forcen, FE | 1 |
| Matsoukas, K | 1 |
| Alici, Y | 1 |
| Schumaker, G | 2 |
| Pacheco, MN | 1 |
| Ruthazer, RR | 1 |
| Maier, AB | 1 |
| Górska, A | 1 |
| Marszałł, M | 1 |
| Sloderbach, A | 1 |
| Hermus, IP | 1 |
| Willems, SJ | 1 |
| Bogman, AC | 1 |
| Brabers, L | 1 |
| Schieveld, JN | 3 |
| Tampi, RR | 1 |
| Tampi, DJ | 1 |
| Ghori, AK | 1 |
| Kersten, A | 2 |
| Reith, S | 1 |
| Corona, A | 2 |
| Colombo, R | 2 |
| Catena, E | 1 |
| Carrasco, G | 1 |
| Baeza, N | 1 |
| Cabré, L | 1 |
| Portillo, E | 1 |
| Gimeno, G | 1 |
| Manzanedo, D | 1 |
| Calizaya, M | 1 |
| Teegarden, BM | 1 |
| Prough, DS | 1 |
| Ritchie, CS | 1 |
| Phillips, JL | 1 |
| Collier, A | 1 |
| Choi, JY | 1 |
| Kim, JM | 1 |
| Kwon, CH | 1 |
| Joh, JW | 1 |
| Lee, S | 1 |
| Park, JB | 1 |
| Ko, JS | 1 |
| Gwak, MS | 1 |
| Kim, GS | 1 |
| Kim, SJ | 1 |
| Lee, SK | 1 |
| Park, JI | 1 |
| Cameron, R | 1 |
| Al-Qadheeb, N | 1 |
| Roberts, R | 1 |
| Fujishiro, K | 1 |
| Kitagawa, Y | 1 |
| Takemura, M | 1 |
| Dotson, B | 1 |
| Freter, S | 1 |
| Koller, K | 1 |
| Dunbar, M | 1 |
| MacKnight, C | 1 |
| Rockwood, K | 1 |
| Carlton, EF | 1 |
| Mahowald, MK | 1 |
| Malas, N | 1 |
| Quinn, S | 1 |
| Sanderson, C | 1 |
| Le, B | 1 |
| Eckermann, S | 1 |
| McCaffrey, N | 1 |
| Devilee, L | 1 |
| Hill, M | 1 |
| Kat, MG | 4 |
| de Jonghe, JF | 6 |
| van der Ploeg, T | 3 |
| van Gool, WA | 6 |
| Eikelenboom, P | 5 |
| Fricchione, GL | 1 |
| Nejad, SH | 1 |
| Esses, JA | 1 |
| Cummings, TJ | 1 |
| Querques, J | 1 |
| Cassem, NH | 2 |
| Murray, GB | 3 |
| Caplan, JP | 2 |
| Rahn, A | 1 |
| Faaij, RA | 1 |
| Ziere, G | 1 |
| Zietse, R | 1 |
| Van der Cammen, TJ | 1 |
| Campbell, N | 1 |
| Ayub, A | 1 |
| Fox, GC | 1 |
| Munger, SL | 1 |
| Ott, C | 1 |
| Guzman, O | 1 |
| Farber, M | 2 |
| Ademuyiwa, A | 1 |
| Singh, R | 1 |
| Reade, MC | 2 |
| O'Sullivan, K | 1 |
| Bates, S | 1 |
| Goldsmith, D | 1 |
| Ainslie, WR | 1 |
| Bellomo, R | 1 |
| van der Hoeven, H | 1 |
| Roodbol, G | 1 |
| van Achterberg, T | 2 |
| Klich-Raczka, A | 1 |
| Piotrowicz, K | 1 |
| Grodzicki, T | 1 |
| Grover, S | 2 |
| Malhotra, S | 1 |
| Bharadwaj, R | 1 |
| Bn, S | 1 |
| Kumar, S | 1 |
| Fong, JJ | 3 |
| Riker, RR | 3 |
| Hill, NS | 2 |
| Robbins, T | 1 |
| Garpestad, E | 2 |
| Joffe, AM | 1 |
| Coursin, DB | 1 |
| Coursin, DR | 1 |
| Balas, MC | 1 |
| Wright, PE | 1 |
| Canonico, AE | 1 |
| Shintani, AK | 1 |
| Meltzer, HY | 1 |
| Mac Sweeney, R | 1 |
| Barber, V | 1 |
| Page, V | 1 |
| Young, JD | 1 |
| Gallo, LE | 1 |
| Palmer, JL | 1 |
| Yennurajalingam, S | 1 |
| Van Ness, PH | 1 |
| Sheldon, T | 1 |
| Bruno, JJ | 1 |
| Warren, ML | 1 |
| van Eijk, MM | 1 |
| Roes, KC | 1 |
| Honing, ML | 1 |
| van der Mast, RC | 3 |
| Kesecioglu, J | 1 |
| Özdemir, B | 1 |
| Çelik, C | 1 |
| Çinar, A | 1 |
| Özşahin, A | 1 |
| Friedlander, M | 1 |
| Passik, S | 1 |
| Campbell, T | 1 |
| Hui, SL | 1 |
| Abernathy, G | 1 |
| Buckley, J | 1 |
| Sing, R | 1 |
| Tricker, J | 1 |
| Zawahiri, M | 1 |
| Keeley, PW | 1 |
| Slor, CJ | 1 |
| Groot, E | 1 |
| Ploeg, TV | 1 |
| Snoeck, M | 1 |
| Schmand, B | 1 |
| Palla, S | 1 |
| Vochteloo, AJ | 1 |
| Moerman, S | 1 |
| van der Burg, BL | 1 |
| de Boo, M | 1 |
| de Vries, MR | 1 |
| Niesten, DD | 1 |
| Tuinebreijer, WE | 1 |
| Nelissen, RG | 1 |
| Pilot, P | 1 |
| Kashyap, GL | 1 |
| Patel, AG | 1 |
| Kumar, V | 1 |
| Chakrabarti, S | 1 |
| Hinderleider, E | 1 |
| Bhat, S | 1 |
| Prommer, E | 1 |
| Wang, EH | 1 |
| Mabasa, VH | 1 |
| Loh, GW | 1 |
| Ensom, MH | 1 |
| Wang, W | 1 |
| Li, HL | 1 |
| Wang, DX | 1 |
| Zhu, X | 1 |
| Li, SL | 1 |
| Yao, GQ | 1 |
| Chen, KS | 1 |
| Gu, XE | 1 |
| Zhu, SN | 1 |
| Tahir, TA | 1 |
| Farewell, D | 1 |
| Bisson, J | 1 |
| Jones, SF | 1 |
| Martin, JJ | 1 |
| Tagarakis, GI | 1 |
| Voucharas, C | 1 |
| Tsolaki, F | 1 |
| Daskalopoulos, ME | 1 |
| Papaliagkas, V | 1 |
| Parisis, C | 1 |
| Gogaki, E | 1 |
| Tsagalas, I | 1 |
| Sataitidis, I | 1 |
| Tsolaki, M | 1 |
| Tsilimingas, NB | 1 |
| Praga, F | 1 |
| Minari, C | 1 |
| Giannotti, C | 1 |
| Castelli, A | 1 |
| Raimondi, F | 1 |
| Selvaraj, AG | 1 |
| Praharaj, SK | 1 |
| Jackson, KC | 2 |
| King, M | 1 |
| Cheung, D | 1 |
| Wolfe, B | 1 |
| Wald, H | 1 |
| Cumbler, E | 1 |
| Sommer, BR | 1 |
| Wise, LC | 1 |
| Kraemer, HC | 1 |
| Uchitomi, Y | 2 |
| Finucane, TE | 1 |
| Gleason, OC | 1 |
| VOLMAT, R | 1 |
| BEAUDOUIN, JL | 1 |
| COLLIN, J | 1 |
| NICOLAS-CHARLES, PJ | 1 |
| ALLERS, G | 1 |
| Awata, S | 1 |
| Skrobik, YK | 1 |
| Bergeron, N | 1 |
| Dumont, M | 1 |
| Gottfried, SB | 1 |
| Lipman, AG | 1 |
| Liu, CY | 1 |
| Juang, YY | 1 |
| Liang, HY | 1 |
| Lin, NC | 1 |
| Yeh, EK | 1 |
| de Rooij, S | 1 |
| de Jonge, E | 1 |
| Vella-Brincat, J | 1 |
| Macleod, AD | 1 |
| Frankenburg, FR | 1 |
| Young, CC | 1 |
| Lujan, E | 1 |
| Kalisvaart, CJ | 1 |
| Hovinga, IM | 1 |
| Hoenders, HJ | 1 |
| Wilterdink, J | 1 |
| Milbrandt, EB | 1 |
| Kong, L | 1 |
| Weissfeld, LA | 1 |
| Clermont, G | 1 |
| Fink, MP | 1 |
| Angus, DC | 1 |
| Schweickert, W | 1 |
| Hall, JB | 1 |
| Leentjens, AF | 2 |
| Nakasato, Y | 1 |
| Servat, J | 1 |
| Amador, F | 1 |
| Teasdale, TA | 1 |
| Kim, JY | 1 |
| Jung, IK | 1 |
| Cho, SH | 1 |
| Kim, L | 1 |
| Kim, SH | 1 |
| Lee, BH | 1 |
| Kim, YK | 1 |
| Mercan, S | 1 |
| Mercan, R | 1 |
| Karamustafalioglu, O | 1 |
| Meijer, K | 1 |
| Slaets, JP | 1 |
| Huyse, FJ | 1 |
| Freire, JM | 1 |
| de Cerqueira Leite, AC | 1 |
| Bueno, DS | 1 |
| Portella, LB | 1 |
| Ribes, SI | 1 |
| Assadi, TC | 1 |
| Colucci, VL | 1 |
| Pereira, ME | 1 |
| Bogaards, MJ | 1 |
| Egberts, TC | 1 |
| Burger, BJ | 1 |
| Legris, P | 1 |
| Wang, MD | 1 |
| Seitz, D | 1 |
| Gill, SS | 1 |
| Leroy, PL | 1 |
| Lacasse, H | 1 |
| Williamson, DR | 1 |
| Dijkstra, M | 1 |
| van Dis, H | 1 |
| Gareri, P | 1 |
| De Fazio, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Ito, H | 1 |
| Harada, D | 1 |
| Hayashida, K | 1 |
| Ishino, H | 1 |
| Nakayama, K | 1 |
| Rea, RS | 1 |
| Battistone, S | 1 |
| Short, MR | 1 |
| Winstead, PS | 1 |
| Lonergan, E | 1 |
| Britton, AM | 1 |
| Luxenberg, J | 1 |
| Wyller, T | 1 |
| Miyaji, S | 1 |
| Yamamoto, K | 1 |
| Hoshino, S | 1 |
| Yamamoto, H | 1 |
| Miyaoka, H | 1 |
| Grover, M | 1 |
| Edwards, F | 1 |
| Hitchcock, K | 1 |
| Stevens, MM | 1 |
| Ozbolt, LB | 1 |
| Paniagua, MA | 1 |
| Kaiser, RM | 1 |
| Füessl, HS | 1 |
| Schrader, SL | 1 |
| Wellik, KE | 1 |
| Demaerschalk, BM | 1 |
| Caselli, RJ | 1 |
| Woodruff, BK | 1 |
| Wingerchuk, DM | 1 |
| Sari, A | 1 |
| Akkaya, C | 1 |
| Taskapilioglu, O | 1 |
| Erer, S | 1 |
| Bora, I | 1 |
| Ramirez, AL | 1 |
| Kanter, GL | 1 |
| Yerevanian, BI | 2 |
| Ciccone, JR | 1 |
| Hales, RE | 1 |
| Holtz, JL | 1 |
| Cassem, EH | 1 |
| Magni, G | 1 |
| De Leo, D | 1 |
| Kulik, AV | 1 |
| Wilbur, R | 1 |
| Di Salvo, TG | 1 |
| O'Gara, PT | 1 |
| Tamai, S | 1 |
| Soares, JC | 1 |
| Fráguas Júnior, R | 1 |
| Nakamura, J | 2 |
| Uchimura, N | 2 |
| Yamada, S | 2 |
| Nakazawa, Y | 2 |
| Sanders, KM | 2 |
| Stern, TA | 1 |
| Metzger, E | 1 |
| Friedman, R | 1 |
| Dixon, D | 1 |
| Craven, J | 1 |
| Marotta, R | 1 |
| Platt, MM | 1 |
| Weisman, H | 1 |
| Derevenco, M | 1 |
| Grau, C | 1 |
| Corbera, K | 1 |
| Raymond, S | 1 |
| Lund, S | 1 |
| Jacobson, P | 1 |
| Byerly, MJ | 1 |
| Christensen, RC | 1 |
| Evans, OL | 1 |
| Pitkälä, K | 1 |
| Trzepacz, PT | 1 |
| Olofsson, SM | 1 |
| Weitzner, MA | 1 |
| Valentine, AD | 1 |
| Baile, WF | 1 |
| Meyers, CA | 1 |
| Akechi, T | 1 |
| Okamura, H | 1 |
| Fukue, M | 1 |
| Kagaya, A | 1 |
| Nishida, A | 1 |
| Oomori, N | 1 |
| Yamawaki, S | 1 |
| Galen, DM | 1 |
| Beck, M | 1 |
| Buchbinder, D | 1 |
| Kunkel, EJ | 1 |
| Matsushima, E | 1 |
| Nakajima, K | 1 |
| Moriya, H | 1 |
| Matsuura, M | 1 |
| Motomiya, T | 1 |
| Kojima, T | 1 |
| Fraser, GL | 1 |
| Richen, P | 1 |
| Blitzstein, SM | 1 |
| Brandt, GT | 1 |
| Paul, KL | 1 |
| Bhatara, VS | 1 |
| Spisla, C | 1 |
| Bünter, M | 1 |
| Manos, PJ | 1 |
| Wu, R | 1 |
| Still, J | 1 |
| Friedman, B | 1 |
| Law, E | 1 |
| Deppe, S | 1 |
| Epperly, N | 1 |
| Orlet, H | 1 |
| Normann, C | 1 |
| Brandt, C | 1 |
| Berger, M | 1 |
| Walden, J | 1 |
| O'Keeffe, ST | 1 |
| Lavan, JN | 1 |
| Hurford, WE | 1 |
| Perrault, LP | 1 |
| Denault, AY | 1 |
| Carrier, M | 1 |
| Cartier, R | 1 |
| Bélisle, S | 1 |
| Strout, D | 1 |
| Tauscher, J | 1 |
| Tauscher-Wisniewski, S | 1 |
| Kasper, S | 1 |
| Conn, DK | 1 |
| Lieff, S | 1 |
| Someya, T | 1 |
| Endo, T | 1 |
| Hara, T | 1 |
| Yagi, G | 1 |
| Suzuki, J | 1 |
| Tabet, N | 1 |
| Howard, R | 1 |
| Ross, DD | 1 |
| Alexander, CS | 1 |
| Arrants, J | 1 |
| Hepp, U | 1 |
| Ehle, G | 1 |
| Uebelhack, R | 1 |
| Cutler, NR | 1 |
| Heiser, JF | 1 |
| Moore, DP | 1 |
| Gelfand, SB | 1 |
| Indelicato, J | 1 |
| Benjamin, J | 1 |
| Nisijima, K | 1 |
| Hirayama, M | 1 |
| Stiefel, F | 1 |
| Holland, J | 1 |
| van den Broek, WM | 1 |
| Moleman, P | 2 |
| Adams, F | 3 |
| Reed, SM | 1 |
| Wise, MG | 1 |
| Timmerman, I | 1 |
| Fernandez, F | 3 |
| Levy, JK | 1 |
| Mansell, PW | 1 |
| Fuller, MA | 1 |
| Sajatovic, M | 1 |
| Moulaert, P | 1 |
| Zisook, S | 1 |
| Braff, DL | 1 |
| Menza, MA | 1 |
| Holmes, VF | 2 |
| Rafuls, WA | 1 |
| Jansen, PA | 1 |
| Bekker, FM | 1 |
| van Nieuwkerk, JF | 1 |
| Nolen, WA | 1 |
| Schols, D | 1 |
| Kavanaugh, JJ | 1 |
| Andersson, BS | 1 |
| Hodgman, CH | 1 |
| Petrova, ES | 1 |
| Raft, DD | 1 |
| Newmark, C | 1 |
| Toomey, T | 1 |
| Heiberg, A | 1 |
| Castaigne, P | 1 |
| Lapresle, J | 1 |
| Chain, F | 1 |
| de Barros-Ferreira, M | 1 |
| Mattos, E | 1 |
| Entin, GM | 1 |
| Voelkel, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium[NCT04750395] | Phase 2 | 80 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU) A Randomized, Blinded, Placebo-controlled Trial[NCT03392376] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2018-06-13 | Active, not recruiting | ||
| Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE) : A Multicenter Randomized Controlled Trial[NCT06029244] | 160 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | |||
| Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733] | 101 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit[NCT03021486] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2017-06-05 | Active, not recruiting | ||
| Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial[NCT03628391] | Phase 3 | 142 participants (Actual) | Interventional | 2018-02-22 | Terminated (stopped due to The study was stopped because of futility of being able to reach a one-day difference between treatment groups in the primary outcome of DCFD in the intended sample size.) | ||
| Baden PRIDe Trial - Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial[NCT02433041] | Phase 4 | 200 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Survey of Management of Analgesia, Sedation and Delirium in ICU Patients in China[NCT04217915] | 800 participants (Anticipated) | Observational | 2021-07-12 | Recruiting | |||
| Virtual Reality Stimulation to Relax and Reduce the Incidence of Delirium[NCT04498585] | 920 participants (Anticipated) | Interventional | 2021-04-14 | Suspended (stopped due to Decreased resources due to COVID-19) | |||
| A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit[NCT01949662] | Phase 2 | 93 participants (Actual) | Interventional | 2014-01-31 | Active, not recruiting | ||
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023] | Phase 3 | 72 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | ||
| Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial[NCT01785290] | Phase 4 | 1,800 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)[NCT04895384] | 600 participants (Anticipated) | Observational | 2021-07-27 | Recruiting | |||
| Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study[NCT02899156] | Phase 4 | 22 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.) | ||
| MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction[NCT01211522] | Phase 3 | 566 participants (Actual) | Interventional | 2011-12-14 | Completed | ||
| Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients[NCT02213900] | Phase 4 | 135 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Pharmacological Management of Delirium[NCT00842608] | 551 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium[NCT00954603] | Phase 3 | 52 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to few delirious patients were enrolled.) | ||
| Structured Cognitive Therapy to Improve Neurocognitive Dysfunction in Older Intensive Care Unit Sepsis Survivors[NCT04081090] | 1 participants (Actual) | Interventional | 2019-01-15 | Terminated (stopped due to Delay due to COVID. Lost funding.) | |||
| Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model?[NCT03199950] | Phase 4 | 1,366 participants (Anticipated) | Interventional | 2017-06-23 | Recruiting | ||
| Early Pharmacological Intervention to Prevent Delirium: Haloperidol Prophylaxis in Older Emergency Department Patients[NCT01530308] | Phase 4 | 242 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Subsyndromal Delirium in Intensive Care Unit, a Multicenter Study[NCT03813459] | 400 participants (Actual) | Observational | 2018-08-01 | Completed | |||
| Effect of Clonidine vs. Dexmedetomidine in Addition to Standard Treatment in Agitated Delirium in Intensive Care Patients: Pilot Study.[NCT04758936] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| Effect of Regional Anaesthesia and General Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Hip Fracture Surgery: a Multicenter Randomized Controlled Trial.[NCT02213380] | 950 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
| Evaluating the Effects of Implementing an Scenario-based Education Initiative and OSCE for Recognition and Management of Delirium in Adult Intensive Care Unit: Randomised Controlled Trial[NCT03642249] | 72 participants (Actual) | Interventional | 2019-11-05 | Completed | |||
| A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium[NCT00505804] | Phase 2 | 20 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Prospective, Double-Blind, Randomized Controlled Trial of Quetiapine as a Treatment for Delirium in Critically Ill Children[NCT03572257] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2019-04-15 | Withdrawn (stopped due to Closed due to inability to enroll) | ||
| Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study[NCT05307003] | 60 participants (Anticipated) | Observational | 2023-04-01 | Recruiting | |||
| Dynamic Light Application to Prevent ICU Acquired Delirium[NCT01274819] | 1,000 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study)[NCT05085808] | Phase 4 | 30 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone[NCT00096863] | Phase 2 | 102 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial[NCT00704301] | Phase 4 | 104 participants (Actual) | Interventional | 2008-11-30 | Terminated (stopped due to The study is prematurely terminated due to a safety issue) | ||
| Randomized Double-Blind Clinical Trial to Compare Haloperidol and Non-Pharmacologic Treatment Versus Non-Pharmacologic Treatment and Placebo, in Elderly Hospitalized Patients With Hypoactive Delirium[NCT02345902] | Phase 3 | 60 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Southern Medical University Clinical Research Project Initiative：Efficacy and Safety of a Multicomponent Physical Therapy Program in Mechanically Ventilated Patient With Sepsis[NCT03406494] | 800 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | |||
| Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium[NCT01187667] | 650 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Objective Assessment of Delirium in Hospitalized Patients[NCT02258386] | 200 participants (Anticipated) | Observational | 2014-10-31 | Not yet recruiting | |||
| Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial[NCT00833300] | 200 participants (Anticipated) | Interventional | 2008-06-30 | Terminated | |||
| A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium[NCT00429676] | Phase 2 | 20 participants (Anticipated) | Interventional | 2005-12-31 | Completed | ||
| ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium[NCT00300391] | Phase 3 | 40 participants (Actual) | Interventional | 2006-03-31 | Terminated (stopped due to Insufficient recruitment to meet aims.) | ||
| Impact of Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block on Postoperative Delirium and Long-term Oucomes in Elderly Patients After Single Knee Arthroplasty[NCT03629483] | Phase 4 | 736 participants (Anticipated) | Interventional | 2018-12-10 | Suspended (stopped due to Trial stopped by the sponsor because of no funding.) | ||
| Impact of Dexmedetomidine Supplemented Intravenous Analgesia on Postoperative Delirium and Long-term Outcomes in Elderly After Orthopedic Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial[NCT03629262] | Phase 4 | 712 participants (Actual) | Interventional | 2018-10-28 | Active, not recruiting | ||
| Impact of Dexmedetomidine Supplemented Analgesia on Delirium and Long-term Outcomes in Elderly After Hip Fracture Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial[NCT04955249] | Phase 4 | 1,440 participants (Anticipated) | Interventional | 2021-11-18 | Recruiting | ||
| Risk Assessment for Postoperative Delirium: Derivation of a Self-Administered Tablet Computer-based Clinical Screening Tool[NCT02377115] | 54 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Cukurova University Faculty of Medicine[NCT02360982] | 120 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| The Effect of Steroid on Reducing Facial Swelling After Orthognathic Surgery[NCT01431014] | Phase 4 | 56 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery[NCT03190642] | Phase 4 | 180 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 30 minutes later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 30 minutes later.
| Intervention | score on a scale (Mean) |
|---|---|
| Escalation Group | -2.6 |
| Rotation Group | -2.4 |
| Combination Group | -2.1 |
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The primary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 24 h later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours after study medication administration
| Intervention | score on a scale (Mean) |
|---|---|
| Escalation Group | -3.6 |
| Rotation Group | -3.3 |
| Combination Group | -3.0 |
The Memorial Delirium Assessment Scale (MDAS) is a 10-item clinician-rated assessment scale validated for assessment of delirium in cancer patients. It examines the level of consciousness, disorientation, memory, recall, attention, disorganized thinking, perceptual disturbance, delusions, psychomotor activity and sleep, assigning a score between 0 to 3, for a total score between 0-30. A total score of 13 or higher indicates delirium. We measured the change in Memorial Delirium Rating scale between baseline and 24 hours. (NCT03021486)
Timeframe: Baseline and 24 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Escalation Group | -2.7 |
| Rotation Group | 1 |
| Combination Group | 0.3 |
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was the proportion of breakthrough restlessness participants with a RASS score of >=1 during the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: 0 or Baseline and 24 hours later
| Intervention | Participants (Count of Participants) |
|---|---|
| Escalation Group | 12 |
| Rotation Group | 7 |
| Combination Group | 9 |
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The Secondary outcome was the percentage of participants with target RASS score of -2 to 0 within the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours later.
| Intervention | Participants (Count of Participants) |
|---|---|
| Escalation Group | 2 |
| Rotation Group | 3 |
| Combination Group | 5 |
This 14-item questionnaire examines both the recalled frequency of 7 delirium symptoms and associated distress in the rater: disorientation to time, disorientation to place, visual hallucinations, tactile hallucinations, auditory hallucinations, delusional thoughts and psychomotor agitation. The score for recalled frequency ranges between 0 and 4, where 0=not present, 1=a little of the time, 2=some of the time, 3=good part of the time, and 4=most or all of the time. The score for distress in the rater related to each delirium symptom also ranges from 0 to 4, where 0=no distress, 1=a little, 2=a fair amount, 3=very much and 4=extremely distressed. Due to an error in the data collection form, the last category was omitted as a choice and thus the score only ranged from 0 to 3. (NCT03021486)
Timeframe: Baseline and Day 3
| Intervention | score on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nursing assessment, disorientation to time - frequency | Nursing assessment, disorientation to place - frequency | Nursing assessment, visual hallucination - frequency | Nursing assessment, tactile hallucination - frequency | Nursing assessment, auditory hallucination - frequency | Nursing assessment, delusional thoughts - frequency | Nursing assessment, psychomotor agitation- frequency | Nursing assessment, disorientation to time - distress | Nursing assessment, disorientation to place - distress | Nursing assessment, visual hallucination - distress | Nursing assessment, tactile hallucination - distress | Nursing assessment, auditory hallucination - distress | Nursing assessment, delusional thoughts - distress | Nursing assessment, psychomotor agitation - distress | |
| Combination Group | 0.2 | 0.3 | -0.7 | -0.9 | -0.4 | 0.2 | -0.4 | -0.5 | -0.4 | -0.4 | -0.5 | -0.2 | -0.1 | -0.8 |
| Escalation Group | -0.8 | -0.9 | -1 | -0.4 | -0.1 | -0.8 | -1.2 | -0.3 | -0.3 | -0.6 | -0.5 | -0.3 | -0.6 | -0.8 |
| Rotation Group | -0.8 | -0.8 | 0 | 0.1 | 0.1 | 0 | -0.8 | -0.3 | -0.3 | 0.1 | 0 | 0 | 0 | -0.5 |
Edmonton Symptom Assessment System (ESAS) has been validated and widely used in different clinical settings, including the acute palliative care unit. It assessed the average symptom intensity of 10 symptoms over the past 24 hours. Each symptom was assessed using an 11-point numeric rating scale, ranging from 0 (none) to 10 (worst). It was measured as change in ESAS as Perceived by Caregivers between baseline and day 1, mean. (NCT03021486)
Timeframe: Baseline and 24 hours
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pain | Fatigue | Nausea | Depression | Anxiety | Drowsiness | Appetite | Feeling of well being* | Shortness of breath | Sleep | |
| Combination Group | -1.1 | 1 | -0.4 | -0.8 | -0.9 | 0.7 | 0.1 | 0 | 0 | -2.7 |
| Escalation Group | -1.3 | -0.5 | 0.1 | -1.4 | -1.5 | -0.2 | -0.3 | 0.2 | 0.8 | -2.7 |
| Rotation Group | -4.1 | -3 | -1.8 | -1.2 | -4.8 | -0.6 | -0.6 | -1.6 | -2.2 | -5.1 |
Use of neuroleptics and benzodiazepines during the first 24 hours was retrieved from the Medication Administration Record. (NCT03021486)
Timeframe: Baseline and 24 hours
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Need for study med dose escalation in first 24 hrs | Benzodiazepine use in first 24 hrs (scheduled) | Benzodiazepine use in first 24 hrs (as needed) | |
| Combination Group | 7 | 0 | 4 |
| Escalation Group | 4 | 1 | 0 |
| Rotation Group | 1 | 0 | 0 |
"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Perceived To Have A High Level of Comfort (More Comfortable) | Perceived To Have A Low Level of Agitation (Less Agitated) | |
| Combination Group | 6 | 6 |
| Escalation Group | 8 | 9 |
| Rotation Group | 10 | 10 |
"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Perceived To Have A High Level of Comfort (More Comfortable) | Perceived To Have A Low Level of Agitation (Less Agitated) | |
| Combination Group | 7 | 7 |
| Escalation Group | 9 | 8 |
| Rotation Group | 9 | 8 |
We also documented the selected adverse effects associated with neuroleptics using the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale. Specifically, we assessed 8 neurologic symptoms (dystonia, rigidity, hypokinesia/akinesia, hyperkinesia, tremor, akathisia, epileptic seizures, paraesthesias). We are reporting only the neurologic symptoms (tremor and akathisia) that had changes during the study. Each item was assigned a score by the research coordinator 0 (absent) to 3 (most severe) based on symptom severity of the last 3 days. (NCT03021486)
Timeframe: Baseline and 3 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Tremor (decreased) | Akathisia (decreased) | |
| Combination Group | 1 | 1 |
| Escalation Group | 0 | 0 |
| Rotation Group | 0 | 0 |
Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: 8 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -2.5 |
| Control Group (Placebo & Haloperidol) | -0.7 |
The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -4.1 |
| Control Group (Placebo & Haloperidol) | -2.3 |
Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 30 minutes
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -3.6 |
| Control Group (Placebo & Haloperidol) | -1.6 |
Number of participants with Richmond Agitation-Sedation Scale score >=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | 8 |
| Control Group (Placebo & Haloperidol) | 22 |
average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | hours (Mean) |
|---|---|
| Flumazenil Group | 54.8 |
| Placebo Group | 58.2 |
average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | milliliters per hour (Mean) |
|---|---|
| Flumazenil Group | 5 |
| Placebo Group | 5.2 |
length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 7.8 |
| Placebo Group | 7 |
Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | days (Median) |
|---|---|
| Flumazenil Group | 12.7 |
| Placebo Group | 9.2 |
number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 23.6 |
| Placebo Group | 24.9 |
defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 9 |
| Placebo Group | 7 |
number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 0 |
| Placebo Group | 0 |
Duration of delirium during the intervention period (NCT01211522)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 4 |
| Ziprasidone | 4 |
| Placebo | 4 |
Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma. (NCT01211522)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 8 |
| Ziprasidone | 8 |
| Placebo | 7 |
(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 1 |
| Ziprasidone | 1 |
| Placebo | 1 |
(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 0 |
| Ziprasidone | 0 |
| Placebo | 0 |
(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 2 |
| Ziprasidone | 0 |
| Placebo | 0 |
"Days from randomization to final, successful ICU discharge, where successful indicates that discharge was followed by at least 48 hours alive. ICU discharge is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU." (NCT01211522)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 5 |
| Ziprasidone | 6 |
| Placebo | 5 |
"Days from randomization to successful hospital discharge, where successful indicates that discharge was followed by at least 48 hours alive." (NCT01211522)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 13 |
| Ziprasidone | 12 |
| Placebo | 13 |
Days from first ICU discharge to next ICU readmission. (NCT01211522)
Timeframe: 90 days after first ICU discharge
| Intervention | days (Median) |
|---|---|
| Haloperidol | 5 |
| Ziprasidone | 5 |
| Placebo | 4 |
"Days from randomization to successful liberation from mechanical ventilation, where successful indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation." (NCT01211522)
Timeframe: 30 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 2 |
| Ziprasidone | 3 |
| Placebo | 3 |
Deaths within the specified timeframe (NCT01211522)
Timeframe: 30-day and 90-day
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 30-day mortality | 90-day mortality | |
| Haloperidol | 50 | 73 |
| Placebo | 50 | 63 |
| Ziprasidone | 53 | 65 |
Test the efficacy of low dose haloperidol in reducing the number of days with delirium among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. (NCT02213900)
Timeframe: Up to 30 days
| Intervention | Days with Delirium (Mean) |
|---|---|
| Haloperidol | 0.3 |
| Placebo | 0.5 |
Test the efficacy of low dose haloperidol in reducing delirium incidence among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. (NCT02213900)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 15 |
| Placebo | 19 |
Test the efficacy of low dose haloperidol in reducing cognitive impairment at post-operative follow-up among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. Cognitive status is assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS measures attention, language, visuospatial/constructional abilities, and memory. It is made up of 12 subtests. The subtests produce 5 index scores and a total scale score. All the subtest scores are summed to calculate a Total Index score. The Total Index score is presented. The Total Index score scale is from 0-100 with higher scores indicating less cognitive impairment. (NCT02213900)
Timeframe: Up to 3 months after hospital discharge on average.
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline RBANS Total Score | 3 Month RBANS Total Score | |
| Haloperidol | 31.7 | 31.8 |
| Placebo | 30.1 | 22.7 |
Test the efficacy of low dose haloperidol in reducing ICU and hospital length of stay among patients who are status post esophagectomy or pneumonectomy compared to placebo. (NCT02213900)
Timeframe: Date of hospital admission through date of hospital discharge, up to 3 weeks on average.
| Intervention | Days (Mean) | |
|---|---|---|
| ICU Length of Stay | Overall Length of Stay | |
| Haloperidol | 2.5 | 9.3 |
| Placebo | 2.8 | 10.2 |
(NCT00842608)
Timeframe: Admission through day 8 of stay
| Intervention | days (Median) |
|---|---|
| Haloperidol Eligible Intervention | 4 |
| Haloperidol Eligible Usual Care | 5 |
| Haldol-Ineligible Arm | 4 |
| Haldol Ineligible Usual Care | 5 |
(NCT00842608)
Timeframe: Participants were followed for the duration of hospital stay, an average of 11 days
| Intervention | days (Mean) |
|---|---|
| Haloperidol Eligible Intervention | 20.2 |
| Haloperidol Eligible Usual Care | 18.6 |
| Haldol-Ineligible Arm | 18.8 |
| Haldol Ineligible Usual Care | 14.9 |
(NCT00842608)
Timeframe: ICU, in-hospital, 30-days post hospitalization
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Eligible Intervention | 20 |
| Haloperidol Eligible Usual Care | 32 |
| Haldol-Ineligible Arm | 11 |
| Haldol Ineligible Usual Care | 8 |
Mortality within 30 days post operation (NCT02213380)
Timeframe: 30 days after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Group RA | 8 |
| Group GA | 4 |
The worst pain score within 7 days post-operation in both groups. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain(0 point) to worst pain (100 points). (NCT02213380)
Timeframe: In 7days post operation
| Intervention | score on a scale (Median) |
|---|---|
| Group RA | 0 |
| Group GA | 0 |
Costs of anesthetic procedure only (NCT02213380)
Timeframe: 1 day after operation
| Intervention | dollars (Median) |
|---|---|
| Group RA | 159 |
| Group GA | 268 |
Length of hospital stay are measured from the anesthesia starting day to the discharge day (NCT02213380)
Timeframe: till the day of discharge from hospital, an average of 7 days
| Intervention | days (Median) |
|---|---|
| Group RA | 7 |
| Group GA | 7 |
Post-operative delirium diagnosed with Confusion Assessment Method (NCT02213380)
Timeframe: in 7 days post operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Group RA | 29 |
| Group GA | 24 |
The worst severity scores of delirium was diagnosed with the DRS-R-98 within 7 days (NCT02213380)
Timeframe: within first 7days post operation
| Intervention | score on a scale (Mean) |
|---|---|
| Group RA | 23.48 |
| Group GA | 24.22 |
Entire expenditure in-hospital (NCT02213380)
Timeframe: till the day of discharge
| Intervention | dollars (Median) |
|---|---|
| Group RA | 5582 |
| Group GA | 5908 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | volume percentage (vol%) of red blood ce (Median) |
|---|---|
| Bright Light Therapy | 28.20 |
| Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | g/dl (Median) |
|---|---|
| Bright Light Therapy | 9.70 |
| Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | days (Median) |
|---|---|
| Bright Light Therapy | 18 |
| Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Bright Light Therapy | 1 |
| Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | thousand cells/uL (Median) |
|---|---|
| Bright Light Therapy | 39 |
| Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | M/uL (Median) |
|---|---|
| Bright Light Therapy | 3.21 |
| Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
| Intervention | units on a scale (Number) |
|---|---|
| Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | K/uL (Median) |
|---|---|
| Bright Light Therapy | 2.30 |
| Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mg/dl (Median) | |
|---|---|---|
| Serum Creatinine | Blood Urea Nitrogen (BUN) | |
| Bright Light Therapy | 0.66 | 9 |
| Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mmol/L (Median) | |||
|---|---|---|---|---|
| Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
| Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
| Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
(NCT00300391)
Timeframe: Daily
| Intervention | Participants (Count of Participants) |
|---|---|
| Delirium | 4 |
| Persistent Coma | 2 |
| No Delirium | 1 |
(NCT00300391)
Timeframe: 90 Days from enrollment in study
| Intervention | Participants (Count of Participants) |
|---|---|
| Delirium | 4 |
| Persistent Coma | 2 |
| No Delirium | 1 |
(NCT00300391)
Timeframe: daily
| Intervention | day (Median) |
|---|---|
| Delirium | 4.5 |
| Persistent Coma | 6 |
| No Delirium | 4 |
(NCT00300391)
Timeframe: Daily
| Intervention | day (Median) |
|---|---|
| Delirium | 9 |
| Persistent Coma | 6 |
| No Delirium | 7 |
Measure of facial swelling will be performed using 3-dimensional photogrammetry. The 3d photo acquisition is non-invasive without radiation concern. The images will be taken before and after surgery to measure and compare the degree of facial swelling. Side effects from the steroid use are expected to be low under normal clinical dosage, but will also be monitored. Symptoms of wound infection, psychosis, and prolonged wound healing will be studied. There should be no long term complication, since the steroid use is one single dose. (NCT01431014)
Timeframe: 1 year
| Intervention | ml (Mean) | ||
|---|---|---|---|
| 36 hours postoperatively | 1week postoperatively | 1month postoperatively | |
| "DexamethasoneHigh-dose" | 167.06 | 61.39 | 29.85 |
| "DexamethasoneLow-dose" | 190.73 | 57.62 | 19.34 |
72 reviews available for haloperidol and Delirium
| Article | Year |
|---|---|
Delirium-associated medication in people at risk: A systematic update review, meta-analyses, and GRADE-profiles.
Topics: Adult; Delirium; Haloperidol; Humans; Prospective Studies | 2023 |
A scoping review of perceptions from healthcare professionals on antipsychotic prescribing practices in acute care settings.
Topics: Antipsychotic Agents; Critical Care; Delirium; Delivery of Health Care; Haloperidol; Humans; Quetiap | 2022 |
Prevention and treatment of traumatic brain injury-related delirium: a systematic review.
Topics: Adult; Aged; Brain Injuries, Traumatic; Delirium; Haloperidol; Humans; Middle Aged; Propofol | 2023 |
Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review.
Topics: Antipsychotic Agents; Cognition; Delirium; Electrocardiography; Haloperidol; Heart; Hospital Mortali | 2019 |
Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review.
Topics: Antipsychotic Agents; Cognition; Delirium; Electrocardiography; Haloperidol; Heart; Hospital Mortali | 2019 |
Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis.
Topics: Bias; Cause of Death; Cognition; Critical Illness; Delirium; Electrocardiography; Haloperidol; Human | 2020 |
Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials.
Topics: Adult; Delirium; Haloperidol; Humans; Intensive Care Units; Length of Stay; Randomized Controlled Tr | 2020 |
Drug therapy for delirium in terminally ill adults.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Delirium; Haloperidol; Humans; Lorazepam; Randomized Co | 2020 |
Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit.
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Delirium; Haloperidol; Humans; Lorazepam; Pall | 2020 |
Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Network Meta-Analysis; Risperidone | 2020 |
Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
Topics: Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Benzodiazepines; Critical Illness; Deep Sed | 2020 |
Antipsychotic Drugs in Prevention of Postoperative Delirium-What Is Known in 2020?
Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Humans; Postoperative Period; Prospective Studies | 2020 |
Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units | 2021 |
Comparative effectiveness of pharmacological interventions to prevent postoperative delirium: a network meta-analysis.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Delirium; Haloperidol; Humans; Network Meta-Analysis; Ph | 2021 |
Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Critical | 2017 |
Update in perioperative medicine: practice changing evidence published in 2016.
Topics: Amines; Analgesics; Anticoagulants; Antipsychotic Agents; Arthritis, Rheumatoid; Blood Transfusion; | 2017 |
Delirium in hospitalized patients: Risks and benefits of antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; | 2017 |
Haloperidol for delirium in critically ill patients - protocol for a systematic review.
Topics: Data Interpretation, Statistical; Delirium; Haloperidol; Humans; Randomized Controlled Trials as Top | 2018 |
Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Postoperative Complication | 2018 |
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Hospitalization; Humans | 2018 |
Palliative Sedation for the Terminally Ill Patient.
Topics: Decision Making; Deep Sedation; Delirium; Haloperidol; Humans; Hypnotics and Sedatives; Midazolam; T | 2018 |
Interventions for preventing intensive care unit delirium in adults.
Topics: Aged; Antipsychotic Agents; Cognition Disorders; Cognitive Behavioral Therapy; Delirium; Female; Hal | 2018 |
Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units; | 2019 |
Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.
Topics: Antipsychotic Agents; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Indenes; Lorazepam; | 2019 |
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Delirium; Evidence-Ba | 2013 |
What do we really know about the treatment of delirium with antipsychotics? Ten key issues for delirium pharmacotherapy.
Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Risperidone | 2013 |
Haloperidol cytotoxicity and its relation to oxidative stress.
Topics: Antipsychotic Agents; Delirium; Gene Expression Regulation; Haloperidol; Humans; Mitogen-Activated P | 2013 |
Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Randomized Controlled Trials a | 2014 |
Management of delirium in palliative care: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholinesterase Inhibitors; Delirium; Disease Ma | 2015 |
Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review.
Topics: Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Dexmedetomidine; Haloperidol; Human | 2015 |
Antipsychotic-induced akathisia in delirium: A systematic review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prevalence; Risperidon | 2016 |
Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence.
Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Hospitalization; Humans; Randomized Controlled Tr | 2016 |
[The neurotoxicity of pyridinium metabolites of haloperidol].
Topics: Antipsychotic Agents; Biotransformation; Brain; Delirium; Haloperidol; Humans; Nausea; Neurodegenera | 2015 |
Acetylcholinesterase Inhibitors for Delirium in Older Adults.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Delirium; Haloperidol; Humans; Randomized Controlle | 2016 |
[Delirium and delirium management in critically ill patients].
Topics: Checklist; Combined Modality Therapy; Critical Care; Delirium; Dexmedetomidine; Early Ambulation; Ev | 2016 |
Neuroleptics in the management of delirium in patients with advanced cancer.
Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloper | 2016 |
Treatment of delirium in supportive and palliative care.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dopamine Antagonists; Haloperidol; Humans; Olanzapi | 2008 |
[Delirium--management in the hospital: diagnosis and treatment].
Topics: Aged; Antipsychotic Agents; Confusion; Delirium; Frail Elderly; Haloperidol; Hospitalization; Humans | 2008 |
Pharmacological management of delirium in hospitalized adults--a systematic evidence review.
Topics: Adult; Anesthetics, Inhalation; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Delirium; Ha | 2009 |
[Delirium in the light of the most recent guidelines].
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Practice Guidelines as Topic; Psychiatric Statu | 2009 |
Intensive care unit delirium.
Topics: Algorithms; Antipsychotic Agents; Critical Care; Delirium; Dexmedetomidine; Diagnostic and Statistic | 2010 |
Delirium at the end of life.
Topics: Analgesics, Opioid; Antipsychotic Agents; Barbiturates; Delirium; Haloperidol; Humans; Incidence; Ne | 2009 |
Role of haloperidol in palliative medicine: an update.
Topics: Delirium; Dopamine Antagonists; Haloperidol; Humans; Nausea; Palliative Care; Vomiting | 2012 |
Haloperidol dosing strategies in the treatment of delirium in the critically ill.
Topics: Antipsychotic Agents; Critical Illness; Delirium; Dose-Response Relationship, Drug; Drug Administrat | 2012 |
ICU delirium: an update.
Topics: Anesthesia, General; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Female; Halope | 2012 |
Confusion, agitation and delirium.
Topics: Antipsychotic Agents; Confusion; Delirium; Haloperidol; Humans; Prevalence; Psychomotor Agitation; R | 2012 |
Brain dysfunction in patients with chronic critical illness.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid | 2012 |
Drug therapy for delirium in terminally ill adult patients.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Delirium; Haloperidol; Humans; Lorazepam; Randomized Co | 2012 |
Delirium.
Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Haloperidol; Humans; Length of Stay; Risk F | 2003 |
[Acute brain syndrome].
Topics: Acute Disease; Antipsychotic Agents; Delirium; Diagnostic and Statistical Manual of Mental Disorders | 2003 |
Drug therapy for delirium in terminally ill patients.
Topics: Antipsychotic Agents; Chlorpromazine; Delirium; Haloperidol; Humans; Lorazepam; Terminally Ill | 2004 |
Haloperidol in palliative care.
Topics: Antipsychotic Agents; Conscious Sedation; Delirium; Haloperidol; Humans; Long QT Syndrome; Nausea; V | 2004 |
Delirium in severely ill young children in the pediatric intensive care unit (PICU).
Topics: Antipsychotic Agents; Child, Preschool; Delirium; Female; Haloperidol; Humans; Intensive Care Units; | 2005 |
Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Hospital Departments; Hospitalization; Humans; Surgery | 2006 |
Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Delirium; Haloperidol; Humans; Treatment Outcome | 2007 |
Delirium dilemma.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; | 2007 |
Antipsychotics for delirium.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Olanzapin | 2007 |
Atypical antipsychotics for the treatment of delirious elders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Delirium; | 2008 |
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati | 2008 |
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati | 2008 |
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati | 2008 |
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati | 2008 |
Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients.
Topics: Aged; Delirium; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Heart Di | 1995 |
[Delirium after open-heart surgery. Prevalence, risk factors and therapeutic approach].
Topics: Cardiac Surgical Procedures; Delirium; Haloperidol; Humans; Intraoperative Period; Postoperative Com | 1994 |
Management of delirium associated with use of the intra-aortic balloon pump.
Topics: Administration, Oral; Adult; Aged; Clinical Protocols; Coronary Disease; Delirium; Diagnosis, Differ | 1993 |
[Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis].
Topics: Aged; Comorbidity; Confusion; Delirium; Dementia; Diagnosis, Differential; Haloperidol; Humans; Neur | 1996 |
Delirium. Advances in diagnosis, pathophysiology, and treatment.
Topics: Adult; Antipsychotic Agents; Brain; Brain Mapping; Child; Delirium; Droperidol; Haloperidol; Humans; | 1996 |
Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients.
Topics: Adult; Critical Care; Delirium; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infusions, In | 1997 |
Delirium in the terminally ill.
Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Geriatric Assessment; Haloperidol; Humans; | 2000 |
Diagnosing and managing delirium in the elderly.
Topics: Aged; Antipsychotic Agents; Delirium; Diagnosis, Differential; Female; Geriatrics; Haloperidol; Huma | 2001 |
Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea.
Topics: Analgesics, Opioid; Anti-Anxiety Agents; Antiemetics; Benzodiazepines; Cathartics; Constipation; Del | 2001 |
[Diagnosis and treatment of delirium].
Topics: Age Factors; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chlormethiazole; Deli | 2002 |
Delirium in cancer patients.
Topics: Aged; Delirium; Diagnosis, Differential; Haloperidol; Humans; Lorazepam; Neoplasms; Neuropsychologic | 1991 |
Choreoathetosis: a sign of lithium toxicity.
Topics: Aged; Athetosis; Chorea; Clonazepam; Delirium; Depressive Disorder; Drug Therapy, Combination; Femal | 1989 |
Management of delirium in terminally ill AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Delirium; Haloperidol; Humans; Injections, Intravenous; Lorazepa | 1989 |
62 trials available for haloperidol and Delirium
| Article | Year |
|---|---|
The effect of the anticholinergic burden on duration and severity of delirium in older hip-surgery patients with and without haloperidol prophylaxis: A post hoc analysis.
Topics: Aged; Cholinergic Antagonists; Delirium; Haloperidol; Humans | 2021 |
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Olanzapine; Psychomotor Agitation | 2022 |
Haloperidol for the Treatment of Delirium in ICU Patients.
Topics: Administration, Intravenous; Adult; Antipsychotic Agents; Critical Care; Delirium; Double-Blind Meth | 2022 |
Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Delirium; Haloperidol; Humans; Intensive Care Units | 2023 |
Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial).
Topics: Critical Illness; Delirium; Dexmedetomidine; Drugs, Investigational; Haloperidol; Humans; Hypnotics | 2023 |
Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial.
Topics: Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Female; Haloperidol; Humans; In | 2023 |
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine; | 2020 |
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.
Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; H | 2020 |
The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan.
Topics: Adult; Coma; Delirium; Haloperidol; Humans; Intensive Care Units; Respiration, Artificial | 2020 |
Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands.
Topics: Adult; Critical Illness; Delirium; Double-Blind Method; Haloperidol; Humans; Intensive Care Units; M | 2020 |
Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial.
Topics: Adult; Cognitive Dysfunction; Delirium; Double-Blind Method; Haloperidol; Humans; Ketamine | 2021 |
Efficacy of quetiapine for delirium prevention in hospitalized older medical patients: a randomized double-blind controlled trial.
Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Quetiapine Fumarate; | 2021 |
Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium.
Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Lorazepam; Psychomotor Agi | 2021 |
Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication.
Topics: Communication; Delirium; Goals; Haloperidol; Humans; Hypnotics and Sedatives; Intensive Care Units; | 2021 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Chi-Square Distrib | 2018 |
Prophylactic Use of Haloperidol and Changes in Glucose Levels in Hospitalized Older Patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Blood Glucose; Delirium; Double-Blind Method; Female; | 2018 |
Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.
Topics: Adult; Aged; Antipsychotic Agents; Critical Illness; Delirium; Dose-Response Relationship, Drug; Dou | 2018 |
The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.
Topics: Adult; Aged; Aged, 80 and over; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Lo | 2018 |
Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium.
Topics: Anesthetics, Dissociative; Antipsychotic Agents; Clinical Trials, Phase IV as Topic; Delirium; Doubl | 2018 |
Lorazepam Added to Haloperidol Effective for Agitated Delirium in End-of-Life Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Female; H | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Preventing Postoperative Delirium After Major Noncardiac Thoracic Surgery-A Randomized Clinical Trial.
Topics: Administration, Intravenous; Antipsychotic Agents; Delirium; Double-Blind Method; Esophagectomy; Fem | 2018 |
Pharmacological Management of Delirium in the Intensive Care Unit: A Randomized Pragmatic Clinical Trial.
Topics: Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Critical Illness; Delirium; Dose-Res | 2019 |
Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study.
Topics: Aged; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Double-Blind Method; Female; | 2019 |
Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU.
Topics: Delirium; Haloperidol; Humans; Intensive Care Units; Pragmatic Clinical Trials as Topic | 2019 |
Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery.
Topics: Aged; Antipsychotic Agents; Cardiac Surgical Procedures; Delirium; Female; Haloperidol; Humans; Male | 2013 |
Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dibenzothiazepines; Double-Blind Method; Female; Halope | 2013 |
Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial.
Topics: Data Collection; Delirium; Double-Blind Method; Ethics, Medical; Haloperidol; Humans; Intensive Care | 2013 |
Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study.
Topics: Adult; Aged; Antipsychotic Agents; Cardiac Surgical Procedures; Checklist; Chi-Square Distribution; | 2014 |
Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Coma; Critical Care; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; Fe | 2013 |
Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Digestive System Surgical Procedures; Elect | 2014 |
A standardized, bundled approach to providing geriatric-focused acute care.
Topics: Academic Medical Centers; Administration, Oral; Aged; Aged, 80 and over; Decision Support Techniques | 2014 |
Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Delirium; Double-Blind Method | 2014 |
In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration.
Topics: Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Delirium; Electrocardiography; Female; Halo | 2015 |
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study.
Topics: Administration, Intravenous; Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Do | 2016 |
Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial.
Topics: Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delirium; Dexmedetomidine; Drug Costs; Drug Resis | 2016 |
The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Elective Surgical Procedures; Female; Halop | 2017 |
Translating Delirium Prevention Strategies for Elderly Adults with Hip Fracture into Routine Clinical Care: A Pragmatic Clinical Trial.
Topics: Aged; Aged, 80 and over; Analgesics; Anti-Dyskinesia Agents; Dehydration; Delirium; Female; Haloperi | 2017 |
Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Australia; Delirium; Double-Blind Method; Female; | 2017 |
Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arthroplasty, Replacement, Hip; Case-Control Studies; | 2008 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy | 2010 |
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; Humans; Inten | 2010 |
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinesterase Inhibitors; Critical Care; Critical Il | 2010 |
Improving delirium care in the intensive care unit: the design of a pragmatic study.
Topics: Aged; Aged, 80 and over; Artificial Intelligence; Benzodiazepines; Cholinergic Antagonists; Critical | 2011 |
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Drug Administration Schedule; Female; | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*.
Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; Humans; Incidence; M | 2012 |
Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cardiac Surgical Procedures; Delirium; Double-Blind M | 2012 |
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.
Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Critical Care; | 2012 |
Haloperidol prophylaxis in critically ill patients with a high risk for delirium.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Double-Blind Method; Female; Haloperidol; Hu | 2013 |
Olanzapine vs haloperidol: treating delirium in a critical care setting.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; De | 2004 |
Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.
Topics: Adult; Antipsychotic Agents; Delirium; Dopamine Plasma Membrane Transport Proteins; Female; Haloperi | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H | 2005 |
Early symptoms in the prodromal phase of delirium: a prospective cohort study in elderly patients undergoing hip surgery.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; APACHE; Cohort Studies; Delirium; Double-Blind Method | 2007 |
[Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol].
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M | 1994 |
A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.
Topics: Adult; AIDS Dementia Complex; Basal Ganglia Diseases; Chlorpromazine; Delirium; Double-Blind Method; | 1996 |
Usage of haloperidol for delirium in cancer patients.
Topics: Aged; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guidelines a | 1996 |
A psychophysiological study of the development of delirium in coronary care units.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Coronary Care Units; Coronary Disease; Delirium; Diazepam | 1997 |
Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Delirium; Female; Haloperidol; | 1997 |
194 other studies available for haloperidol and Delirium
| Article | Year |
|---|---|
Comment on:"Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial".
Topics: Cognitive Dysfunction; Delirium; Double-Blind Method; Haloperidol; Humans; Ketamine | 2022 |
Concerns over haloperidol for treating delirium in older people.
Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Humans | 2022 |
A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Hydroxyzine; Hypnotics and Sedatives; Intensive | 2022 |
Concerns With Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.
Topics: Adult; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units | 2022 |
Agents intervening against delirium in the intensive care unit trial-Protocol for a secondary Bayesian analysis.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Delirium; Haloperidol; Humans; Intensive Care Units | 2022 |
Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Japan; Neoplasms; Palliative C | 2022 |
Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database.
Topics: Aged; Antipsychotic Agents; Cross-Sectional Studies; Delirium; Demography; Female; Haloperidol; Huma | 2022 |
Haloperidol for Treatment of ICU Delirium - Progress or Setback?
Topics: Antipsychotic Agents; Critical Care; Delirium; Haloperidol; Humans; Intensive Care Units | 2022 |
Haloperidol-induced myoclonus in a patient with delirium.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Myoclonus | 2023 |
Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases.
Topics: Antipsychotic Agents; Delirium; Dyspnea; Haloperidol; Humans; Retrospective Studies; Transdermal Pat | 2023 |
Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Delirium; Dementia; Female; Ha | 2023 |
In adults with delirium in the ICU, haloperidol did not increase number of days alive out of the hospital at 90 d.
Topics: Adult; Antipsychotic Agents; Delirium; Haloperidol; Hospitals; Humans; Intensive Care Units | 2023 |
[Haloperidol is not the first choice for every case of delirium].
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Medicine | 2023 |
Delirium in Older Persons: Prevention, Evaluation, and Management.
Topics: Aged; Cognition; Delirium; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Inp | 2023 |
[Additive therapies : Intensive care studies from 2018-2019].
Topics: Critical Care; Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2020 |
Critical Care Prophylaxis. Sometimes Less Is More.
Topics: Adult; Critical Care; Critical Illness; Delirium; Haloperidol; Humans | 2019 |
Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium.
Topics: Adult; Aged; Antipsychotic Agents; Critical Illness; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A | 2020 |
An unwanted reaction by the use of Haloperidol in hyperkinetic delirium.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans | 2021 |
Anabolic steroids-induced delirium: A case report.
Topics: Adult; Aggression; Antipsychotic Agents; Delirium; Haloperidol; Humans; Male; Quetiapine Fumarate; T | 2020 |
Pharmacologic Treatment for Hypoactive Delirium in Adult Patients: A Brief Report of the Literature.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cohort Studies; Delirium; Haloperidol; Humans | 2021 |
Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study.
Topics: Clonidine; Cohort Studies; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units; Pr | 2021 |
Haloperidol and Quetiapine for the Treatment of ICU-Associated Delirium in a Tertiary Pediatric ICU: A Propensity Score-Matched Cohort Study.
Topics: Antipsychotic Agents; Child; Cohort Studies; Delirium; Female; Haloperidol; Humans; Intensive Care U | 2021 |
Delirium in the NICU: Risk or Reality?
Topics: Adult; Antipsychotic Agents; Child; Delirium; Haloperidol; Humans; Infant, Newborn; Intensive Care U | 2021 |
Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.
Topics: Adult; Aged; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Female; Haloperidol; H | 2021 |
Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units; Male; Middle Aged; Olanza | 2021 |
Effect of Low Dose Haloperidol and Quetiapine on QTc Interval in Hospitalized Elderly Patients With Delirium.
Topics: Aged; Antipsychotic Agents; Delirium; Electrocardiography; Haloperidol; Humans; Quetiapine Fumarate | 2021 |
Haloperidol in the ICU: A Hammer Looking for a Nail?
Topics: Delirium; Haloperidol; Humans; Intensive Care Units | 2021 |
Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Catatonia; Delirium; Diagnosis, Differential; | 2021 |
In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo.
Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Palliative Care; Risperido | 2017 |
Delirium: Use Antipsychotics When Appropriate and Appropriately.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M | 2017 |
A National Multicenter Survey on Management of Pain, Agitation, and Delirium in Intensive Care Units in China.
Topics: Delirium; Dexmedetomidine; Fentanyl; Haloperidol; Humans; Hypnotics and Sedatives; Intensive Care Un | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research is Needed-Reply.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Population pharmacokinetics of haloperidol in terminally ill adult patients.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Computer Simulation; Delirium; Female; Haloper | 2017 |
Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Butyrophenones; Delirium; Female; Halope | 2017 |
Hypertensive bipolar: chronic lithium toxicity in patients taking ACE inhibitor.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Bipolar Disorder; Delirium; Diagnosis | 2017 |
Two unusual cases of protracted inter-ictal delirium following electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Delirium; Electroconvulsive Therapy; Haloperidol; Humans; Lorazepam; Ma | 2017 |
Haloperidol for delirium prevention: uncertainty remains.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Uncertainty | 2018 |
Hydroxyethyl starch is associated with early postoperative delirium in patients undergoing esophagectomy.
Topics: Age Factors; Aged; Antipsychotic Agents; Blood Transfusion; Cerebrovascular Disorders; Crystalloid S | 2018 |
Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Clinical Protocols; Critical Illness; Del | 2018 |
'Palliative sedation'? A retrospective cohort study on the use and labelling of continuously administered sedatives on a palliative care unit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Conscious Sedatio | 2018 |
Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study.
Topics: Adolescent; Adult; Antipsychotic Agents; Brazil; Canada; Critical Care; Delirium; Europe; Haloperido | 2018 |
Haloperidol and delirium in the ICU: the finger pointing to the moon.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Critical Care; Delirium; Female; Haloperidol; | 2018 |
The influence of oxygen delivery during cardiopulmonary bypass on the incidence of delirium in CABG patients; a retrospective study.
Topics: Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Delirium; Female; Haloperidol; Humans; Inciden | 2018 |
Prophylactic Haloperidol for Critically Ill Adults.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Prophylactic Haloperidol for Critically Ill Adults.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Prophylactic Haloperidol for Critically Ill Adults-Reply.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Haloperidol serum concentrations in critically ill patients included in the REDUCE study.
Topics: Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Dopamine Antagonists in ICU Delirium.
Topics: Critical Illness; Delirium; Dopamine Antagonists; Haloperidol; Humans; Intensive Care Units; Piperaz | 2018 |
[A Multicenter Questionnaire Survey of Postoperative Delirium -National Hospital Organization, Surgery and Anesthesia Network Group-].
Topics: Aged; Anesthesia; Delirium; Female; Haloperidol; Humans; Incidence; Postoperative Complications; Pos | 2016 |
Discussions about palliative sedation in hospice: Frequency, timing and factors associated with patient involvement.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Decision Making, Shared; Delirium | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. Reply.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Acute and long-term effects of haloperidol on surgery-induced neuroinflammation and cognitive deficits in aged rats.
Topics: Animals; Cognition; Cognitive Dysfunction; Cytokines; Delirium; Fear; Haloperidol; Hippocampus; Male | 2019 |
Harms From Haloperidol for Symptom Management in Palliative Care-a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Middle A | 2019 |
Impact of an educational workshop upon psychiatrists' attitudes towards delirium care.
Topics: Aged; Attitude of Health Personnel; Delirium; Dementia; Diagnosis, Differential; Haloperidol; Humans | 2019 |
Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
Topics: Antipsychotic Agents; Critical Illness; Decision Making; Delirium; Haloperidol; Health Care Surveys; | 2013 |
Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital.
Topics: Aged; Aged, 80 and over; Aging; Anti-Anxiety Agents; Delirium; Dopamine Antagonists; Dose-Response R | 2013 |
[Delirium prevention and treatment in elderly hip fracture].
Topics: Aged; Anesthesia, Epidural; Anesthesia, General; Benzodiazepines; Cognition Disorders; Combined Moda | 2014 |
Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting?
Topics: Antipsychotic Agents; Critical Care; Delirium; Haloperidol; Humans; Male; Middle Aged; Neuroleptic M | 2013 |
What's new on the post-ICU burden for patients and relatives?
Topics: Antipsychotic Agents; Cognition Disorders; Critical Illness; Delirium; Family; Haloperidol; Humans; | 2013 |
Patterns of opiate, benzodiazepine, and antipsychotic drug dosing in older patients in a medical intensive care unit.
Topics: Aged; Analgesics, Opioid; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Cohort Studies; Conn | 2013 |
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Female; Haloperidol; Huma | 2013 |
High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life.
Topics: Adult; Antipsychotic Agents; Delirium; Drug Substitution; Female; Gastrointestinal Neoplasms; Halope | 2014 |
Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Comorbidity; Delirium; Female; Haloperidol; Ho | 2013 |
Delirium in acute promyelocytic leukemia patients: two case reports.
Topics: Antineoplastic Agents; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Idarubicin; Leuk | 2013 |
Can critical-care delirium be treated pharmacologically?
Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male | 2013 |
Hope for haloperidol in delirium.
Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male | 2013 |
Prophylactic haloperidol: too early to lose hope.
Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male | 2013 |
Prophylactic haloperidol: too early to lose hope - author's reply.
Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male | 2013 |
Correlation of haloperidol concentration in blood and cerebrospinal fluid: a pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Biomarkers; Delirium; Elective Surgical Procedures; Female; Haloperidol; Hu | 2014 |
Adverse events of haloperidol for the treatment of delirium in critically ill children.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Critical Illness; Delirium; Female; Halop | 2014 |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol; | 2015 |
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F | 2016 |
[Perioperative management of off-pump CABG for a 93-year-old man].
Topics: Aged, 80 and over; Anesthesia; Brain; Cerebrovascular Circulation; Consciousness Monitors; Coronary | 2014 |
Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients.
Topics: Age Factors; Aged; Aged, 80 and over; APACHE; Cognition Disorders; Delirium; Dose-Response Relations | 2015 |
Does haloperidol cause delirium?
Topics: Delirium; Female; Haloperidol; Humans; Intensive Care Units; Male | 2015 |
Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium: a systematic review of quantitative evidence protocol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans; Inte | 2015 |
"Delirium" Is No Delirium: On Type Specifying and Drug Response.
Topics: Delirium; Female; Haloperidol; Humans; Intensive Care Units; Male | 2015 |
The authors reply.
Topics: Delirium; Female; Haloperidol; Humans; Intensive Care Units; Male | 2015 |
Early Identification of Subsyndromal Delirium in the Critically Ill: Don't Let the Delirium Rise!
Topics: Antipsychotic Agents; Critical Illness; Delirium; Female; Haloperidol; Humans; Male | 2016 |
What to Do When Haloperidol Fails to Treat Agitated Delirium: Is Dexmedetomidine the Next Step?
Topics: Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives | 2016 |
Predictors of Mortality for Delirium in Palliative Care.
Topics: Comorbidity; Delirium; Haloperidol; Humans; Palliative Care; Prognosis | 2016 |
Use of Dexmedetomidine in Liver Transplant Recipients With Postoperative Agitated Delirium.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dexmedetomidine; Female; Haloperidol; Humans; Hypnotics | 2016 |
Delirium associated with olanzapine use in the elderly.
Topics: Aged; Antipsychotic Agents; Aortic Aneurysm; Benzodiazepines; Delirium; Haloperidol; Humans; Male; O | 2017 |
Look again at psychedelic drugs.
Topics: Anxiety; Delirium; Depression; Diazepam; Hallucinogens; Haloperidol; Humans; Lorazepam; Midazolam; P | 2016 |
Comparing Dexmedetomidine With Haloperidol for the Treatment of Hyperactive Delirium in Nonintubated ICU Patients.
Topics: Antipsychotic Agents; Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives; Inten | 2016 |
Management of Multifactorial Infant Delirium with Intravenous Haloperidol in the Setting of Over Sedation and Poor Enteral Absorption.
Topics: Administration, Intravenous; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Hypnotics | 2017 |
Postoperative delirium.
Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Electrocardiography; Electroencephalography | 2008 |
Haloperidol and delirium: management or treatment?
Topics: Delirium; Dopamine Antagonists; Haloperidol; Humans | 2009 |
Delirium due to a drug-drug interaction of lithium and an NSAID.
Topics: Accidental Falls; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressi | 2009 |
Tackling agitated delirium--the tip of the iceberg.
Topics: Antipsychotic Agents; Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives; Psych | 2009 |
Implementation of a delirium assessment tool in the ICU can influence haloperidol use.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Female; Guideline Adherence; Haloperidol; Humans; Inser | 2009 |
Delirium in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Delirium; Dose-Response Relationship, Dru | 2009 |
Why all the confusion about confusion?
Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Drug Therapy, Combination; Halope | 2010 |
Free your MIND and the rest will follow: decoding delirium in the intensive care unit.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units; Piperazines; Postoperativ | 2010 |
A national survey of the management of delirium in UK intensive care units.
Topics: Antipsychotic Agents; Delirium; Delivery of Health Care; Haloperidol; Humans; Intensive Care Units; | 2010 |
Neuroleptic dose in the management of delirium in patients with advanced cancer.
Topics: Adult; Affective Symptoms; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Delirium; Dose | 2010 |
Factors associated with persistent delirium after intensive care unit admission in an older medical patient population.
Topics: Age Factors; Aged; Analgesics, Opioid; Analysis of Variance; Critical Care; Delirium; Dementia; Halo | 2010 |
Study of rivastigmine for delirium in intensive care is stopped after deaths.
Topics: Antipsychotic Agents; Critical Care; Death, Sudden; Delirium; Double-Blind Method; Drug Therapy, Com | 2010 |
Relief by electroconvulsive therapy for postsurgical delirium in malignant catatonia.
Topics: Antipsychotic Agents; Cardiac Surgical Procedures; Catatonia; Coronary Artery Bypass; Delirium; Elec | 2010 |
Mortality associated with delirium after hip-surgery: a 2-year follow-up study.
Topics: Aged; Antipsychotic Agents; Delirium; Female; Follow-Up Studies; Haloperidol; Hip; Hospitalization; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Aripiprazole and haloperidol in the treatment of delirium.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol; | 2011 |
Anesthesia and postoperative delirium in older adults undergoing hip surgery.
Topics: Aged; Anesthesia, Conduction; Anesthesia, General; Cognition Disorders; Delirium; Female; Haloperido | 2011 |
Neuroleptic prescription pattern for delirium in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M | 2011 |
Delirium risk screening and haloperidol prophylaxis program in hip fracture patients is a helpful tool in identifying high-risk patients, but does not reduce the incidence of delirium.
Topics: Aged; Aged, 80 and over; Cohort Studies; Delirium; Female; Haloperidol; Hip Fractures; Humans; Incid | 2011 |
Unusual presentation of a patient with GBL withdrawal: a case report.
Topics: 4-Butyrolactone; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chlorpromazine; Delirium; Hal | 2011 |
Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Critical Care; Delirium; Drug Monitoring; Halope | 2011 |
Randomised control trials for delirium: current evidence and statistical methods.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Risperidone | 2012 |
Delirium, sigma-1 receptors, dopamine, and glutamate: how does haloperidol keep the genie in the bottle?*.
Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Postoperative Complications | 2012 |
The largest ever trial demonstrating effectiveness of intensive care unit delirium prophylaxis--we must know more!
Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Postoperative Complications | 2012 |
Delayed onset and prolonged interictal delirium following electroconvulsive therapy.
Topics: Cholinesterase Inhibitors; Delirium; Depressive Disorder; Donepezil; Electroconvulsive Therapy; Foll | 2012 |
Unsafe use of intravenous haloperidol: evaluation of recommendation-concordant care in hospitalized elderly adults.
Topics: Age Factors; Aged; Antipsychotic Agents; Colorado; Death, Sudden, Cardiac; Delirium; Electrocardiogr | 2013 |
Is dopamine administration possibly a risk factor for delirium?
Topics: Delirium; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; Injections, Intravenous; Logi | 2002 |
[Management of psychiatric symptoms in cancer patients].
Topics: Antidepressive Agents; Delirium; Depression; Disease Management; Dopamine Antagonists; Haloperidol; | 2002 |
Delirium at the end of life.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Terminal | 2002 |
Haloperidol should be used sparingly.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Practice Guidelines as Topic; United States | 2002 |
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope | 1964 |
Efficacy of risperidone in treating the hyperactive symptoms of delirium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Fe | 2004 |
Reply to the comment by Skrobik et al.
Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delirium; Haloperidol; Humans; Olanzapine; | 2004 |
Pharmacological treatment of delirium in the intensive care unit.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units | 2004 |
Intravenous ziprasidone for treatment of delirium in the intensive care unit.
Topics: Antipsychotic Agents; Bone Transplantation; Critical Care; Delirium; Haloperidol; Humans; Male; Midd | 2004 |
[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Delirium; Halo | 2004 |
[Delirium in a 73-year-old man after many years of unwise use of betahistine].
Topics: Aged; Betahistine; Blood-Brain Barrier; Cerebral Infarction; Delirium; Haloperidol; Histamine Agonis | 2004 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Agitation in the critically ill patient: a marker of health or a plea for treatment?
Topics: Antipsychotic Agents; Conscious Sedation; Critical Care; Critical Illness; Delirium; Haloperidol; Ho | 2005 |
Delirium in the older hospitalized patient.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Confusion; Delirium; Glasgow Coma Scale; Haloperido | 2005 |
Case report: delirium associated with ovarian hyperstimulation syndrome.
Topics: Adult; Chorionic Gonadotropin; Delirium; Female; Haloperidol; Humans; Infertility; Ovarian Hyperstim | 2005 |
[Lithium use and perioperative management].
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Lithium; Male; Middle Aged; Oxazepam; Periopera | 2005 |
Reading and writing: psychoanalytical treatment in a case of paranoia.
Topics: Adult; Antipsychotic Agents; Art Therapy; Combined Modality Therapy; Delirium; Female; Haloperidol; | 2005 |
[Paranoid delirium of cognition].
Topics: Antipsychotic Agents; Child; Cognition Disorders; Delirium; Haloperidol; Humans; Middle Aged; Parano | 2005 |
Perioperative haloperidol usage for delirium management.
Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Humans; Length of Stay; Perioperative Care; Posto | 2006 |
Perioperative haloperidol to prevent postoperative delirium.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Drug Th | 2006 |
[Delirium in critically ill children in a paediatric intensive care unit].
Topics: Antipsychotic Agents; Child, Preschool; Critical Illness; Delirium; Diagnosis, Differential; Female; | 2006 |
Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.
Topics: Acute Disease; Aged, 80 and over; Alzheimer Disease; Amitriptyline; Antipsychotic Agents; Cholinergi | 2007 |
[Psychiatry and sleep disorders--delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I | 2006 |
Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections, | 2007 |
Clinical inquiries. What steps can reduce morbidity and mortality caused by hip fractures?
Topics: Aged; Analgesics; Antibiotic Prophylaxis; Antipsychotic Agents; Bacterial Infections; Cephalosporins | 2007 |
[Delirium in the old age].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dementia; Diagnosis, | 2008 |
Laryngeal dystonia in a patient with bilateral anterior cerebral artery infarction during treatment of delirium with haloperidol.
Topics: Antipsychotic Agents; Delirium; Dystonia; Haloperidol; Humans; Infarction, Anterior Cerebral Artery; | 2008 |
Intravenous haloperidol.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Infusions, Parenteral | 1980 |
Case report of a possible interaction between neuroleptics and carbamazepine.
Topics: Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Delirium; Drug Interactions; Female; Haloperi | 1984 |
Issues in reimbursement for consultation-liaison psychiatry.
Topics: Coronary Artery Bypass; Delirium; Haloperidol; Humans; Insurance, Health, Reimbursement; Male; Middl | 1984 |
Complex management of postcardiotomy delirium.
Topics: Cardiac Surgical Procedures; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; | 1983 |
Delirium and stereotypy from anticholinergic antiparkinson drugs.
Topics: Adult; Aged; Benztropine; Delirium; Diazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; E | 1982 |
Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.
Topics: Adult; Alcoholism; Cardiomyopathy, Dilated; Delirium; Dose-Response Relationship, Drug; Electrocardi | 1993 |
Continuous infusion of haloperidol.
Topics: Aged; Critical Care; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Middle Age | 1993 |
Delirium associated with a combination of sertraline, haloperidol, and benztropine.
Topics: 1-Naphthylamine; Adult; Benztropine; Delirium; Depressive Disorder; Drug Interactions; Drug Therapy, | 1996 |
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperido | 1996 |
Steroid psychosis after orthognathic surgery: a case report.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid | 1997 |
Steroid psychosis after orthognathic surgery: a case report.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid | 1997 |
Steroid psychosis after orthognathic surgery: a case report.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid | 1997 |
Steroid psychosis after orthognathic surgery: a case report.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid | 1997 |
Treating delirium among elderly patients.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Delirium; Diagnosis, Differential; | 1997 |
Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium.
Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections, Intravenous; Middle Aged; P | 1997 |
Anticholinergic delirium possibly associated with protriptyline and fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cholinergic Antagonists; | 1997 |
[Treatment with haloperidol of clozapine-triggered drug-induced delirium].
Topics: Antipsychotic Agents; Clozapine; Delirium; Haloperidol; Humans; Male; Middle Aged; Schizophrenia, Pa | 1997 |
The duration of delirium in medical and postoperative patients referred for psychiatric consultation.
Topics: Aged; Delirium; Dementia; Female; Haloperidol; Humans; Length of Stay; Male; Middle Aged; Patient Ca | 1997 |
Neuroleptic malignant syndrome in a burn patient.
Topics: Accidents, Occupational; Adult; Antipsychotic Agents; Bromocriptine; Burns; Dantrolene; Debridement; | 1998 |
Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dyskinesia, Drug-Induced; Female | 1998 |
Clinical significance of delirium subtypes in older people.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prospective Studies; P | 1999 |
Sedation in the intensive care unit.
Topics: Analgesics, Opioid; Anesthetics, General; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Benzod | 1999 |
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Coronary Artery Bypass; Critical Care; Delirium; Elect | 2000 |
Treatment of patients with delirium.
Topics: Delirium; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Haloperidol; Humans; Pract | 2000 |
A survey on the drug therapy for delirium.
Topics: Antipsychotic Agents; Delirium; Drug Approval; Drug Utilization Review; Haloperidol; Humans; Japan; | 2001 |
Optimising management of delirium. Patients with delirium should be treated with care.
Topics: Age Factors; Aged; Antipsychotic Agents; Contraindications; Delirium; Drug Administration Schedule; | 2001 |
Intravenous haloperidol.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Infusions, Parenteral; Injections, Intravenous | 2001 |
[Dangerous side effects of lithium therapy].
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Brain Stem; Delirium; Diabetes Insipidus; D | 1977 |
A question on haloperidol treatment for delirium.
Topics: Delirium; Haloperidol; Humans | 1978 |
Rapid treatment of delirium in critically ill patients.
Topics: Accidents, Traffic; Adult; Burns; Critical Care; Delirium; Drug Administration Schedule; Haloperidol | 1977 |
Letter: Definition of "dementia" after haloperidol.
Topics: Delirium; Haloperidol; Humans; Psychoses, Substance-Induced; Terminology as Topic | 1976 |
Using intravenous haloperidol to control delirium.
Topics: Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Infusions, Intravenous | 1992 |
[ICU syndrome].
Topics: Aged; Anxiety; Benzodiazepines; Clomipramine; Critical Care; Delirium; Depressive Disorder; Female; | 1991 |
[A psychiatric disorder in an intensive care unit].
Topics: Critical Care; Delirium; Haloperidol; Humans | 1991 |
High-dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aortic balloon pump.
Topics: Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Infusions, Intravenous; Intra-Aorti | 1991 |
Emergency intravenous sedation of the delirious, medically ill patient.
Topics: Critical Care; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Hydromorphone; Infusions, I | 1988 |
Neurotoxicity resulting from a combination of lithium and loxapine.
Topics: Adult; Delirium; Dibenzoxazepines; Drug Therapy, Combination; Haloperidol; Humans; Lithium; Loxapine | 1989 |
Treatment of acute nonspecific delirium with i.v. haloperidol in surgical intensive care patients.
Topics: Acute Disease; Aged; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Postoperat | 1989 |
Delirium: recognition and management in the older patient.
Topics: Aged; Aging; Anti-Anxiety Agents; Benzodiazepines; Delirium; Diagnosis, Differential; Drug-Related S | 1986 |
Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines.
Topics: Aged; Anti-Anxiety Agents; Basal Ganglia Diseases; Benzodiazepines; Delirium; Drug Therapy, Combinat | 1988 |
[Lasting neurologic injury in therapeutic lithium plasma levels].
Topics: Aged; Delirium; Drug Combinations; Female; Haloperidol; Humans; Lithium | 1989 |
[Delirium in the general hospital].
Topics: Aged; Benzodiazepines; Cognition Disorders; Delirium; Haloperidol; Humans; Middle Aged; Prognosis; R | 1988 |
Treatment of severe, refractory agitation with a haloperidol drip.
Topics: Acute Disease; Cerebral Infarction; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; M | 1988 |
Emergency pharmacotherapy of delirium in the critically ill cancer patient.
Topics: Adult; Aged; Delirium; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Humans; Infusion | 1986 |
A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder.
Topics: Bipolar Disorder; Carbamazepine; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; M | 1985 |
[Hallucinatory paraphrenic syndrome in the course of schizophrenia].
Topics: Adult; Automatism; Azo Compounds; Delirium; Hallucinations; Haloperidol; Humans; Illusions; Paranoid | 1967 |
The organic brain syndrome.
Topics: Alcoholic Intoxication; Attention; Chlordiazepoxide; Delirium; Haloperidol; Humans; Hydrocephalus; M | 1974 |
[Delirious reactions in acute pancreatitis].
Topics: Acute Disease; Adult; Cerebral Ventriculography; Chlorprothixene; Cholecystectomy; Delirium; Diazepa | 1969 |
[Complex persisting dyskinesia, secondary to neuroleptic therapy].
Topics: Aged; Butyrophenones; Delirium; Electromyography; Extrapyramidal Tracts; Female; Haloperidol; Humans | 1969 |
[Developmental study on night sleep during episodes of manias or acute depressions].
Topics: Acute Disease; Adult; Bipolar Disorder; Chlorpromazine; Delirium; Electroencephalography; Female; Ha | 1969 |
[The clinical picture and therapy of alcoholic psychoses in old age].
Topics: Acute Disease; Apomorphine; Barbiturates; Cerebrovascular Disorders; Delirium; Delusions; Female; Ha | 1970 |
[Complications caused by anonymous preclinical medication].
Topics: Amitriptyline; Antidepressive Agents; Barbiturates; Bromides; Cannabis; Chlordiazepoxide; Delirium; | 1970 |